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ABSTRACT
Allergie rhinitis affects a large proportion o f the worldwide population, and its 
constituent symptoms include nasal blockage, rhinorrhoea and nasal pruritus. 
Tissue acidosis is a component of inflammation and ischaemia, and this occurs in 
inflammatory conditions, such as that found in the mucosa of patients with 
allergic rhinitis.
Acid sensing ion channels, ASICs, are a family o f ligand-gated cation channels, 
activated by acid (pH 7.4 — 5.5), which belong to the amiloride-sensitive 
degenerin/epithelial Na+ channel (ENaC) superfamily. Stimulation of these 
receptors on nerves leads to a variety of sensations including pain and mechano- 
perception, while epithelial expression linked to airway secretion has been 
reported in cystic fibrosis cell lines. A description and function of these receptors 
in human upper airways has not been described.
Our aim was to determine if  the acid-sensing ion channel receptors, specifically 
type 3 (ASIC-3), are present, upregulated, and functional, in the nasal mucosa of 
patients with allergic rhinitis, and if  they play a role in the allergic rhinitis 
constituent symptom of rhinorrhoea.
Eosinophils are almost always found in the mucosa, the submucosa and in the 
nasal secretions of subjects with allergic rhinitis. We hypothesised that the 
eosinophil has a major role to play in inflammatory conditions such as allergic 
rhinitis, and may have a role in acting via ASIC receptors, inducing them, or 
mediating them to react.
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Our findings, as shown through real time polymerase chain reaction quantification 
of ASIC receptors in nasal biopsies, demonstrated no mRNA for ASIC-1 or 
ASIC-2. ASIC-3 was seen in both healthy controls and allergic rhinitis, in whom 
it was significantly increased (p<0.02, n =11). Immunohistochemistry 
demonstrated the presence o f ASIC-3 receptors on the apical surface of epithelial 
cells, mucous glands and nerve cells o f both control and allergic rhinitis subjects, 
but expression was increased in the latter.
Functional experiments with lactic acid (pH 7.0) demonstrated significantly 
increased nasal secretary responses on the ipsilateral but not contralateral side, 
which were blocked by amiloride (ImM).
Eosinophils and released major basic protein (MBP) were found in association 
with airway nerve cells, mucous glands and epithelial cells. Eosinophil granule 
proteins increased the expression o f ASIC-3 and showed a significant 
upregulation of ASIC-3 in an ERK-kinase dependent manner.
Thus, functional ASIC-3 receptors are present in nasal mucosa, and their 
expression is upregulated in allergic rhinitis via released eosinophil granule 
proteins. This data indicate a link with tissue inflammation, which may lead to 
enhanced nasal secretion in allergic rhinitis.
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A B B R E V IA T IO N S
AR Allergic rhinitis
ARIA Allergic rhinitis and its impact on asthma
ASIC Acid-sensing ion channel
ASL Airway surface liquid
CGRP Calcitonin gene-rclated peptide
CFTR Cystic fibrosis transmembrane receptor
DRASIC Dorsal root acid sensing ion channel
ECP Eosinophilic cationic protein
ENaC Epithelial sodium channel
EPO Eosinophil peroxidase
ERK Extracellular-related kinase
GM-CSF Granulocyte/macrophage colony stimulating factor
ICAM-1 Intracellular adhesion molecule 1
IgA Immunoglobulin A
IgE Immunoglobulin E
IL Interleukin
ITR Immediate-type reactions
LPR Late-phase responses
MAP Mitogen-activated protein
MBP Major basic protein
MPO Myeloperoxidase
NANC Non-adrenergic non-cholinergic nerves
SIP Sphingosine-1 -phosphate
SEM Standard error o f mean
TNF-cx Tumour necrosis factor alpha
TRPV1 Transient vanilloid receptor subtype VI
VCAM Vascular cell adhesion molecule 1
WHO World Health Organisation
C H A P T E R  1 -  IN T R O D U C T IO N
The nasal cavity extends from the nostrils anteriorly, to the posterior nasal 
apertures and then onto the nasopharynx. The nasal cavity is bound below by the 
hard palate, which separates the nasal cavity from the oral cavity. It is bound 
above by the cribriform plate of the ethmoid bone and body of the sphenoid bone, 
separating it from the cranium. The septum forms the central strut or scaffolding 
and separates the two nasal airways (Jones N, 2001). This divides the nasal cavity 
into clearly distinct right and left nasal cavities, and is a partly cartilaginous and 
partly bony partition (McMinn RMH, 1990). The separation of the nasal cavity is 
important as it is used to discriminate reflex responses from local responses 
(Sheahan P, 2006) and it is the basis of some work in this thesis.
The lateral wall of each nasal cavity is marked by three longitudinally oriented 
projections extending from anterior to posterior, one above another, called the 
inferior, middle, and superior turbinates. These turbinates are composed of bone 
covered by mucosa. They extend medially and downwards, and may occupy a 
significant volume o f the nasal cavity. The inferior turbinate is the largest of the 
three and may occasionally extend as far as the nasal septum medially, and the 
nasal floor inferiorly. The minimum cross-sectional area of the nose is commonly 
found in the region o f the anterior portion o f the inferior turbinate. This is the 
nasal valve area and is the area o f maximal resistance in the nasal airway. It is 
formed by the overlap between the upper and lower lateral cartilages, the inferior 
turbinate and the septum (Jones N, 2001). The space below and lateral to the
1.1 Nasal anatomy:
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inferior turbinate is known as the inferior meatus, and receives the opening o f the 
nasolacrimal duct.
The middle turbinate is smaller than the inferior turbinate. A narrowing in nasal 
cross-sectional area is usually found in the region o f the head of the middle 
turbinate; however, the cross-sectional area here is in most cases much greater 
than that near the head of the inferior turbinate. The space below and lateral to the 
middle turbinate (the middle meatus) receives the openings of the maxillary, 
frontal, and anterior ethmoid sinuses (Dykewicz MS, 2003).
The superior turbinate is smaller than either the inferior or middle turbinates. The 
posterior ethmoid sinuses drain into the superior meatus, which is below and 
lateral to the superior turbinate (McMinn 1990). The sphenoid sinus drains via its 
own separate ostium into the nasal cavity posterosuperiorly.
1.2 Nasal physiology
The primary functions of the nose are associated with defensive and homeostatic 
mechanisms o f the body (Sarin S, 2006), and the nose plays this role by cleaning 
and humidifying inhaled air (Baraniuk JN, 2008). These functions encompass 
olfaction, air conditioning resonance, and trapping of airborne particles, whilst the 
inferior, middle, and superior turbinates in the nasal cavity promote air filtration, 
humidification, and temperature regulation (Dykewicz MS, 2003).
Warming, humidification, and conditioning of inspired air are enhanced by blood 
flow through the submucosal capacitance vessels. Expansion of these vessels 
results in increased blood flow, which leads to increased heat exchange, as well as
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swelling o f the nasal lining, which enhances contact between the mucosa and 
inspired air (Hilberg O, 2002).
These processes are under strict physiological control, which depends on local 
mucosal feedback systems, and sensory and autonomic reflexes (Baraniuk JN, 
2008).
The functional structures of the nasal cavity are the walls of the anterior nasal 
vestibule, inferior, middle and superior turbinates, and the regulatory engine of 
the nasal mucosa (Baraniuk JN, 2008). The considerable surface area of the 
mucosa overlying the turbinates render the nose ideally suited to fulfilling these 
roles.
Other physiological functions o f the nose include sensation, immunology, 
mucociliary clearance, and regulation of the nasal cycle and airflow dynamics 
(Jones N, 2001). As air enters the nose during inspiration, it encounters two areas 
of narrowing: one at the internal nasal valve, near the junction o f the nasal septum 
and the upper lateral nasal cartilages, and one in the region of the head of the 
inferior turbinate. These areas o f narrowing convert the laminar flow of air into a 
turbulent flow, thus maximizing contact between the inspired air and the nasal 
mucosa.
A thin layer of mucus overlies the nasal epithelium. This mucus blanket functions 
to trap dust and other inspired particles, thus preventing them from reaching the 
lower airway. The mucus dynamically moves trapped matter via ciliary action to
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the nasopharynx (Hilberg O, 2002) (Dylcewicz MS, 2003). This is termed 
mucociliary clearance, and allows maintenance of the health and defence of the 
nose (Jones N, 2001) (Nathan RA, 2005 ).
Any defects in mucociliary clearance may promote mucus retention within 
the nasal cavity, thus reducing nasal airflow. Mucociliary function can be 
assessed by measures such as the saccharine test, which is in part subjective, 
as well as more objective tests such as the measurement of ciliary beat 
frequency and ciliary ultrastructure (Nathan RA, 2005 ).
This mucus fulfils the two roles o f trapping and transporting airborne particles. 
Particles in the turbulent inhaled airstream stick onto nasal mucus, which lines the 
nasal cavity. Eighty percent of particles larger than 12.5juM are filtered from the 
air through this blanket o f mucus, which is then moved by coordinated waves of 
cilia, from the front o f the nose to the nasopharynx (Jones N, 2001). Here, the 
mucus blanket can be swallowed or expectorated.
It is thought that inflammatory mediators bring about improvement in mucociliary 
transport and an increase in ciliary beat frequency during an allergic nasal 
reaction. Experiments on patients with allergic rhinitis with allergen challenge 
have proven inconclusive however, in terms of clearly showing an increase in 
mucociliary transport (Jones N, 2001).
1.3. The nasal cycle
Airflow through the two nasal cavities is normally asymmetrical as a result of 
spontaneous changes in nasal airway patency, which are often reciprocal in nature.
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These resulting cyclic fluctuations in nasal patency constitute the nasal cycle 
(Hanif J, 2000). In the “classical”, or “ideal” nasal cycle, alternating, reciprocal 
changes in nasal patency are seen, with a periodicity ranging from 30 minutes to 
several hours (Gungor A, 1999 ) (Huang ZL, 2003 ). However, this classical 
pattern, characterized by true reciprocity and periodicity, is seen in only a 
minority of subjects (Gungor A, 1999 ) (Hanif J, 2000) (Huang ZL, 2003 ). On 
the other hand, spontaneous fluctuations in nasal patency, without contralateral 
reciprocity or a regular period, are seen in most individuals (Gungor A, 1999 ) 
(Hanif J, 2000) (Huang ZL, 2003 ).
These changes in nasal cycle are potentially important in the variations within 
subjects today, as seen in my study. This will be discussed later.
1.4 The nasal epithelium
The ciliated epithelium overlies a basement membrane and submucosa. The 
submucosa consists o f serous and seromucous glands, nerves, vasculature, and 
other cellular elements (Dykewicz MS, 2003).
The nasal cavity is lined throughout by a ciliated pseudostratified columnar 
epithelium, except superiorly, near the cribriform plate (the olfactory area) and 
partly on the superior and middle turbinates (Jones N, 2001), where specialised 
olfactory epithelium is found; and at the very anterior part of the nasal cavity (the 
nasal vestibule), anterior to the limen nasi (the groove between the upper and 
lower lateral nasal cartilages), which is lined by skin (McMinn RMH, 1990).
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In terms of nasal mucosa in inflammatory conditions such as allergic rhinitis, it is 
known that bradykinin plays a role as an important inflammatory mediator 
(Shirasaki H, 2009). Immunohistochemical studies have shown immunoreactivity 
for both B1 and B2 bradykinin receptors, in epithelial cells, submucosal glands, 
fibroblast, vascular smooth muscle, vascular endothelial cells, and macrophages. 
The B2 receptor expression was found in peripheral nerve fibers, unlike B1 
expression, which was not observed in nerves (Shirasaki H, 2009).
1.5 The nerve supply of the nose
Sensory innervation of the nose arises from the olfactory nerve, the ethmoidal 
nerve, and the maxillary branches o f the trigeminal nerve (Baraniuk JN, 1990). 
The bulk of the sensory nerve supply enters the nose via the sphenopalatine 
foramen in the nasopalatine nerve. The anterior ethmoidal nerve provided by the 
ophthalmic division of the trigeminal nerve provides some sensory supply to the 
nasal cavity.
Sensory nerves transmit signals from the mucosa causing pruritus and the motor 
reflexes of sneezing, and act on the sympathetic and parasympathetic reflexes that 
affect secretions and increased vascularity o f the nasal mucosa (Sarin S, 2006). 
Nasal blood flow is controlled by vasoconstricting sympathetic nerves and 
vasodilating nitrergic (whereby transmission is mediated by nitric oxide) nerves 
(Ogawa F, 2010). Stimulation of the sympathetic nerves is known to decrease the 
nasal blood flow in rats. In the absence of nerve stimulation, the nasal blood flow
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is regulated predominantly by sympathetic nerves with vasoconstriction, rather 
than nitrergic nerves with vasodilation (Ogawa F, 2010).
All nasal symptoms o f rhinitis can be triggered through neural pathways which 
can be chronically upregulated in the presence o f inflammation. Stimulation of 
these nerves results in release of neuropeptides, causing vasodilatation, increased 
permeability, glandular activation and activation of other immune cells of 
inflammation.
The parasympathetic innervation of the nose derives from the facial nucleus of the 
brain stem and the superior salivatory nucleus (Sarin S, 2006). In terms of the 
secretomotor nerve supply, preganglionic parasympathetic nerves traverse 
through branches of the facial nerve. These nerves reach the pterygopalatine 
ganglion via the greater superficial petrosal nerve. They are joined by 
postganglionic sympathetic fibres from around the internal carotid artery which 
have relayed in one o f the cervical sympathetic ganglia. The greater superficial 
and deep petrosal nerves reach the pterygopalatine ganglion via the nerve of the 
pterygoid canal. Preganglionic fibres of the greater superficial petrosal nerve and 
vidian nerve synapse at the sphenopalatine ganglion, with postganglionic fibres 
following the posterior nasal nerve to innervate serous and mucous glands. 
Parasympathetic fibres synapse in the ganglion, while sympathetic fibres pass 
through or around these ganglia. From there, the postganglionic nerves travel to 
the nasal cavity in the nasopalatine nerve (Konno A, 1979). In effect this means 
that the local nerves o f the parasympathetic division have small post ganglionic
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branches which may be better able to adapt to local changes, a term called neural 
plasticity.
Sympathetic nerves supply blood vessels, leading to vasoconstriction and hence 
decongestion by releasing noradrenaline, which acts on a-receptors (Riechelmann
H, 1994). Stellate ganglion blockade prevents the decrease in nasal mucosal blood 
flow produced by peripheral cold provocation, demonstrating the role of the 
sympathetic nervous system in decongestive reflexes. Parasympathetic nerves 
supply nasal glands, causing glandular secretion, by releasing acetylcholine, 
which acts on muscarinic M3 receptors (Kaliner MA, 1992 ) (Okayama M, 1993 ) 
(Nakaya M, 2002).
In addition to the well defined sympathetic and parasympathetic nerves, a poorly 
described, as far as humans nerves are concerned, loosely termed non-adrenergic 
non-cholinergic (NANC) nerve supply also exists. These may play a role in 
diverse aspects of nasal function including recognition and response to irritant 
chemicals, pH changes and locally produced inflammatory mediators. Activation 
of these nerves may lead to responses such as pain, nasal secretion, itch and a 
sense of blockage and congestion (Sarin S, 2006). This thesis is focussed in part 
on understanding the role o f these nerves.
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Allergic rhinitis is clinically defined as an immunolobulin-E mediated 
inflammation of the mucosal lining o f the nose (Bousquet J, 2008), induced after 
allergen exposure via an IgE-mediated immune response (Bousquet J, 2004). This 
inflammation leads to the accumulation of eosinophils and T-lymphocytes 
(Kramer MF, 2004). This results in 3 cardinal symptoms of sneezing, nasal 
obstruction, and mucous discharge, in association with rhinorrhoea, nasal pruritus, 
and nasal congestion (Kramer MF, 2004) (Sheahan P, 2005).
By definition, symptoms should occur during two or more consecutive days, 
lasting greater than one hour on most days, and should be reversible 
spontaneously or with treatment. Both allergic rhinitis and asthma constitute 
systemic inflammatory conditions and often co-exist.
Allergic rhinitis is by far the most frequent manifestation of atopy (45%) (Kramer 
MF, 2004), and affects 15-25% of the population o f the western world. The 
prevalence of allergic rhinitis has seen an increase over the past 50 years, with a 
prevalence of 3.5% each decade (van Aas K, 1997). Although the reasons for the 
increasing prevalence are not clear, and increasing prevalence is seen most 
commonly in developing countries, AR appears to be somehow associated with 
the Western lifestyle. Causes and risk factors for the disease can be suitably 
identified, be they indoor or outdoor allergens, and even exposure to occupational 
agents.
1.6 Allergic rhinitis: definition
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There is common acceptance that allergic rhinitis has a significant impact on 
quality o f life, impairing both work and school performance and has an economic 
impact through medication expenses and lost time at work (Juniper EF, 1994) 
(Malone DC, 1997). In fact, it accounts for up to an estimated 3% of all medical 
visits (Fomadley JA, 1996).
1.7 Allergic rhinitis: classification
The classification and update o f allergic rhinitis and its management was 
concluded in 1999, during a World Health Organisation (WHO) workshop. 
Suggestions for improvement and standardisation were tabled by experts in the 
field, under the Allergic Rhinitis and Its Impact on Asthma (ARIA) forum. This 
was based on all available literature evidence up till December 1999.
The similarities between lung and nasal mucosa highlighted the ‘one airway, one 
disease’ concept. Over 85%-95% of asthmatics have rhinitis (Togias AG, 2000), 
and conversely, 10-40% of patients with rhinitis have asthma. Hence, pathologic 
findings in the nose may also apply to asthma.
Allergic rhinitis was newly classified as intermittent or persistent, as opposed to 
seasonal, perennial, and occupational. This is a new classification, and not 
synonymous with the old classification. Severity was classified as mild or 
moderate/severe, emphasizing its impact on quality of life.
In intermittent allergic rhinitis, symptoms are present for either fewer than 4 days 
per week, or for less than 4 consecutive weeks; whereas in persistent allergic
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rhinitis, symptoms are present for more than 4 days per week, and for longer than 
4 consecutive weeks (Bachert C, 2002).
Mild allergic rhinitis is characterised by normal sleep, no troublesome symptoms, 
no impairment of daily activities, and no impairment o f school or work 
performance. Moderate-severe allergic rhinitis is characterised by abnormal sleep 
or presence o f troublesome symptoms or impairment of daily activities or 
impairment of school or work performance (Bachert C, 2002).
When comparing the new classification to the old, Sheahan et al showed good 
correlation of patients’ symptomatic and secretory responses with the new ARIA 
classification, and felt that it was easier to use and more inclusive of commonly 
encountered patients than the traditional classification into seasonal and perennial 
forms (Sheahan P, 2007)
1.8 Diagnosis of allergic rhinitis:
The diagnosis of allergic rhinitis rests on the combination o f a positive history of 
allergic symptoms, and diagnostic tests confirming that these symptoms are due to 
allergy (Fomadley JA, 1996) (Dykewicz MS, 2003). These diagnostic tests are 
based on the identification o f a positive IgE-mediated skin prick test or serum- 
specific IgE. The skin prick test has the best positive predictive value for allergy 
of 48.7% (Tschopp JM, 1998). Allergic symptoms include sneezing, nasal 
pruritus, rhinorrhoea, and nasal congestion, and are reversible spontaneously or 
with treatment. There may be a temporal association between exposure to 
allergens and the onset of symptoms.
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Diagnostic tests to confirm that the symptoms are due to allergy are directed 
towards the detection of free or cell-bound allergen-specific IgE antibodies. This 
may be achieved either through in-vivo skin testing on in vitro testing, via blood 
tests (Fomadley JA, 1996). Despite specific IgE antibodies to environmental 
allergens playing a key role in allergy, their presence, as evidenced by skin tests 
or in vitro tests, indicates sensitization, but it does not directly imply the 
occurrence of clinical allergy (Fuiano N, 2010).
The usual technique o f skin testing is skin-prick testing. Skin-prick testing has 
superior sensitivity and specificity to skin scratch testing, and is less time and 
resource consuming than intradermal dilution testing, a technique which involves 
multiple intradermal injections of serially diluted antigen samples (Fomadley JA, 
1996).
A  drop of antigen is placed on the skin and a lancet needle passed through the 
droplet. A relatively controlled quantity of antigen can thus delivered into the 
dermal layer, with the distance placed on the skin reproducible each time 
(Fomadley JA, 1996). The advantages of skin prick testing are that it 
demonstrates an actual response in the patient’s skin unlike in-vitro testing, which 
only demonstrates the presence of IgE antibodies. It is rapid and reasonably 
straightforward, and is highly sensitive, and allows for a wide antigen selection 
(Fomadley JA, 1996).
The disadvantages are that it is not suitable for children or uncooperative patients, 
patients with dermatographia or extensive dermatitis, or patients who are very 
allergic and in whom anaphylaxis is a possible risk. In addition, patients must
discontinue anti-histamines, as these may interfere with skin prick testing. Reports 
suggest rates of 10-20%, to up to 50% rates of negative test reactions to histamine, 
following different antihistamine usage (dos Santos RV, 2009 ).
In-vitro serum tests involve detection of allergen-specific IgE in the serum of 
patients. The measurement o f total IgE is of little predictive value in allergic 
rhinitis. However, the measurement of allergen-specific IgE is of importance, and 
is of similar value to skin tests (Bachert C, 2002). The advantages of in-vitro 
testing are that there is no risk of anaphylaxis, it is suitable in uncooperative 
patients, and it is not affected by antihistamine treatment (Fomadley JA, 1996). 
However, it is expensive, and results may take several weeks. In addition, caution 
has to be exercised when interpreting the results of in-vitro tests, as the presence 
of allergen-specific IgE is not in itself sufficient to diagnose allergic disease. The 
demonstration that the symptoms are due to the results o f IgE mediated 
inflammation is not possible by in-vitro testing. Thus the assessment by the 
physician o f the clinical picture is necessary (Fomadley JA, 1996).
Another test that may be of use in future studies is the analysis of specific IgE in 
the nasal mucosa of patients with allergic rhinitis (Fuiano N, 2010). It is thought 
that some patients with rhinitis and negative skin test results may have IgE only in 
the nasal mucosa, probably due to local production. Techniques for measurement 
of nasal IgE are not routinely available. The test involves placing an allergen- 
coupled cellulose derivative onto a 2-hole applicator strip covered with a 
permeable membrane (to avoid adhesion of nasal mucosa to the substrate) and
28
then positioning the strip in the upper tract of the internal ostium for 10 minutes. 
Results are read as a colorimetric reaction and expressed on a scale of 0 (negative) 
to 4 (highly positive) using a calibration curve (Fuiano N, 2010). The absence of 
specific IgE in the nasal mucosa could account for the absence of rhinitis 
symptoms in most individuals sensitized to aeroallergens (Fuiano N, 2010).
Other useful assessment tests include nasal acoustic tests to detect changes in 
nasal cavity size, which may reflect nasal congestion. In acoustic rhinometry, a 
sound impulse is generated and transmitted through a tube of known dimensions 
into the nostrils. The reflected echoes are analysed, with the size and pattern of 
the reflections indicative of the structure and dimensions o f the nasal airways 
(Nathan RA, 2005 ). A major advantage of acoustic rhinometry over other 
methods, such as rhinomanometry, is that it is a simple technique to use and 
requires minimal patient cooperation (Nathan RA, 2005 ).
Measurement of biomarkers in exhaled condensate, such as adenosine, (Vass G, 
2006) have been attempted but they too have validation issues which have limited 
their usefulness, and as such, shall not be discussed in detail in this thesis.
1.9 Pathology of Allergic Rhinitis -  The IgE
Allergic rhinitis is manifested through the interaction of cells and their mediators 
with cytokines, chemokines, and adhesion molecules which are coordinated in a 
complex network to produce local inflammation at a molecular biological level. 
Allergy is caused in part by IgE over-production (Watanabe M, 2008). This may 
be in response to common environmental antigens, food and other allergens.
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Common allergens include proteins and glycoproteins in airborne dust mite faecal 
particles, cockroach residues, animal danders, molds, and pollens (Fomadley JA, 
1996) (Dykewicz MS, 2003). Allergy can however, occur even in the absence of a 
specific allergen. In fact, recent studies would suggest that it may be conceivable 
that high levels of IgE may persistently stimulate mast cells and/or basophils to 
release inflammatory mediators before exposure to allergens and may modify or 
reinforce the subsequent allergic reactions evoked by allergen challenge 
(Watanabe M, 2008).
IgE itself is a product o f complex interactions between mast cells, B-cells, T-cells 
and basophils, and is present in lymphoid tissue, nasal and bronchial mucosa. It is 
the aggregation of receptor-bound IgE molecules on exposure to specific allergens 
that results in the production and action of mediators such as histamine and 
leukotrienes, which in turn cause the allergic response of allergic rhinitis. IgE 
evokes inflammation via the activation of mast cells, which then degranulate 
chemical mediators, such as histamines and prostaglandins, by the interaction of 
IgE and allergen (Watanabe M, 2008). This results in the immediate-type 
reactions (ITR), such as the wheal-and-flare skin response in skin prick tests. This 
corresponds to the immediate phase of allergic rhinitis, which is characterized by 
the symptoms of sneezing, nasal discharge and nasal congestion (Okubo K, 2008). 
The late-phase responses (LPR) occur hours after the ITR. Late phase responses 
are characterized by a cellular infiltrate comprised of lymphocytes, neutrophils, 
and eosinophils. The LPR is also a mast cell-dependent reaction that is probably
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initiated by mast cell-derived cytokines, such as TNF-a and IL-4, and possibly by 
several chemokines. The cytokines stimulate the expression of cell adhesion 
molecules on dermal endothelial cells, and the chemokines mediate the chemo- 
attraction o f effector cells (Watanabe M, 2008). Nasal congestion is the major 
complaint in the delayed phase of allergic rhinitis (Olcubo K, 2008).
Eosinophils are almost always found in the mucosa, the submucosa and in the 
nasal secretions o f subjects with AR (Klemens C, 2007). Mast cells are present in 
increased numbers in the epithelium and the submucosa, and CD4+ T-cells are 
increased in number during the pollen season in patients with intermittent 
symptoms. Moreover, in allergic patients, there is an increase in Langerhan-like 
cells (CD1+) during the pollen season (Howarth, 1995). IgE-induced mast cell 
activation principally induces CD4+ T cell recruitment into the airways (Maezawa 
Y, 2004). This then plays an important role in enhancing Th2 cell-mediated 
eosinophilic airway inflammation by recruiting Th2 cells into the site of allergic 
inflammation (Maezawa Y, 2004). Hence, it is likely that these cells are important 
in the pathogenesis and the local interaction of these cells and their mediators 
with the specific structures in the nose, such as the epithelium, nerves, mucous 
glands, and blood vessels.
Histamine has become known as the mediator o f allergic and anaphylactic 
reactions, and is released by mast cells and basophils. Although still one of the
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major effectors o f the allergic reaction, many other mediators produced by 
different cell types are also involved.
Direct stimulation of the nose outside o f neural stimulation can cause rhinorrhoea 
and nasal congestion, via the local phenomenon of the action o f histamine acting 
directly on HI and H2 receptors on nasal vasculature end organs. Another focus 
of this project will be to address local and neural secretory responses.
1.10 Neuropathology in rhinitis
Many symptoms o f rhinitis can be mediated by nerves (Sarin S, 2006), with the 
nerves o f the nose playing a role in the neurogenic effects o f allergic rhinitis. 
These include sensory, sympathetic and parasympathetic nerves.
Sensory nerves transmit signals from the mucosa causing pruritus and the motor 
reflexes o f sneezing, and act on the sympathetic and parasympathetic reflexes that 
affect secretions and increased vascularity of the nasal mucosa. Pruritus and 
sneezing represent the tactile sensation and central reflex symptoms of rhinitis 
(Sarin S, 2006), but reflex-type symptoms can occur even in the absence of nasal 
abnormality or nasal irritation. All nasal symptoms of rhinitis can be triggered 
through neural pathways. Increased neural activity can be chronically upregulated 
in the presence o f inflammation.
Rhinorrhoea is also a product o f the reflex activation of submucosal glands, and a 
contralateral secretory response to certain external stimuli is tenned the neural 
reflex (Sarin S, 2006). In response to a sensory stimulus, neural stimulation can
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also lead to vasodilatation and subsequent nasal vascular congestion via decreased 
sympathetic outflow in conjunction with increased parasympathetic discharge. 
This has been shown to occur in the contralateral nostril also. However, it is also 
likely that there are local effects e.g. secretion of fluid from vascular leakage and 
directly from epithelial cells.
1 . 1 1  N e r v e  a c t i v a t i o n  a s  a  m e c h a n i s m  i n  A R  a n d  n e u r a l  h y p e r  
r e s p o n s i v e n e s s .
When subjects with allergic rhinitis who are currently symptomatic are challenged 
with histamine, bradykinin, hyperosmolar saline, or capsaicin, they typically 
demonstrate an enhanced symptomatic and secretory response compared to that 
seen in normal subjects.
When the propensity of a patient to develop nasal symptoms in response to an 
allergic stimulus becomes abnormally exaggerated, this phenomenon is known as 
nasal hyper responsiveness (Nathan RA, 2005 ).
The mechanism for sensorineural hyper responsiveness has not been clearly 
identified. A major component of neural hyper responsiveness is caused by 
upregulation of neural activity, whereby any stimulus of even average intensity 
can cause symptoms. Patients with allergic rhinitis have a more marked hyper 
responsiveness of their nasal mucosa than those without allergic rhinitis (Nathan 
RA, 2005 ). Whether this is due to increased neural activity is debatable but can
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be investigated by comparing bilateral nasal secretions attributed to a certain 
external stimulus challenge on a designated nostril as presented in this thesis.
Nasal hyper responsiveness may explain the exaggerated symptomatic responses 
of patients with allergic rhinitis to a variety of non-allergic triggers, such as 
cigarette smoke, noxious odours, and cold air The mechanisms of this response 
have been widely investigated. It is well recognised that histamine and 
bradykinin stimulate sensory nerves in the nasal epithelium. 
Immunohistochemical studies have clearly delineated expression of both B1 and 
B2 bradykinin receptors in epithelial cells, submucosal glands, fibroblast, vascular 
smooth muscle, vascular endothelial cells, and macrophages, with B2 receptor 
expression found in peripheral nerve fibers (Shirasaki H, 2009).
Stimulation of these sensory nerves in turn leads to the symptoms of nasal 
irritation / pruritus, sneezing, as well as the stimulation of local and centrally 
mediated neural reflexes. This then stimulates further glandular secretion and 
nasal congestion (Togias A, 2000).
Reflex-mediated secretion occurs on the ipsilateral side of the nose but 
distinguishing these from local responses is difficult. A good way to distinguish 
local responses from reflex responses is the study of the contralateral reflex. The 
contralateral reflex is an example of a centrally mediated neural reflex. This is 
shown by applying a chemical to one side of the nose and then measuring the 
contralateral secretory response to this unilateral challenge. Secretions obtained
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on the contralateral side at the time of stimulation contain high levels of glandular 
proteins, such as secretory IgA (Raphael GD, 1989), lactoferrin (Raphael GD, 
1989) (Riccio MM, 1996), lysozyme (Raphael GD, 1989) (Reynolds CJ, 1999), 
and low levels of albumin (Riccio MM, 1996). This would indicate that these 
secretions arise from nasal glandular secretion and not from vascular leakage.
In contrast, ipsilateral secretory responses to histamine and bradykinin contain 
high levels of both glandular proteins and albumin, suggesting that they originate 
from both glandular secretion and vascular leakage.
The contralateral response is significantly attenuated by applying a local 
anaesthetic or an anticholinergic agent (Baroody FM, 1994), and this would 
suggest strong evidence for a neural mechanism for the contralateral secretory 
response to unilateral nasal challenge.
Increased contralateral secretory reflexes are seen after unilateral nasal challenge 
in allergic subjects with a variety of agents including histamine and hypertonic 
saline (Raphael GD, 1989) (Baroody FM, 1993), and bradykinin (Baraniuk JN, 
1994) (Riccio MM, 1996) (Reynolds CJ, 1999). However, such a response was 
not clearly identified with isotonic saline and was not evident in patients with AR 
who had intermittent AR, and who were studied when they were asymptomatic 
(Sanico AM, 1999). This data indicates that there is neural hyper responsiveness 
to a variety of mediators, but the mechanisms of upregulation, physiological 
factors, and the nerve types mediating this response are not identified.
Neural mechanisms in allergic rhinitis may also have effects through local axonal 
reflexes. There is evidence that stimulation of nociceptive nerves in the nasal 
mucosa by bradykinin, capsaicin, or hyperosmolar saline leads to the local release 
of neuropeptides, including substance P, neurokinin A, and calcitonin gene- 
related peptide (CGRP), which may then mediate glandular secretion or vascular 
leakage (Baraniuk JN, 1990) (Sanico AM, 1997) (Baumgarten CR, 1997) 
(Baraniuk JN, 1999). Increased levels of substance P-like immunoreactivity have 
been reported in nasal lavages of atopic subjects compared to controls, with 
further increases in these levels after allergen challenge (Nieber K, 1992).
Nasal challenge with capsaicin, a specific stimulus for nociceptive C-fibres, leads 
to increased levels of albumin and fibrinogen, markers of vascular leakage, in 
nasal lavage fluid in subjects with allergic rhinitis. This response is significantly 
diminished after pre-treatment with lignocaine, but not after pre-treatment with 
atropine, implying that the effects of capsaicin on vascular leakage are mediated 
by local neural reflexes (Sanico AM, 1998).
The effects of bradykinin on vascular leakage are not affected by lignocaine, 
implying that bradykinin acts directly on blood vessels (Sanico AM, 1998). 
However, repeated nasal challenge with bradykinin in allergic subjects leads to 
tachyphylaxis for induction of ipsilateral albumin levels, suggesting that these 
direct effects of bradykinin are augmented by a neural mechanism. Because 
bradykinin does not induce contralateral albumin levels, this neural contribution is 
suggested to reflect local axonal reflexes rather than centrally mediated reflexes 
(Reynolds CJ, 1999).
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To summarise the relationship between nerve activation and AR, the mechanisms 
underlying secretory hyper responsiveness are not fully elucidated. Several 
possible mechanisms exist. In the first place, the sensory nerves may be hyper 
responsive to nociceptive stimuli. Secondly, the efferent nerves may be hyper 
responsive, and thus cause potentiated stimulation of the nasal glands. Thirdly, 
there may be centrally-mediated hyper responsiveness, with enhanced 
transmission of signals from afferent nociceptive fibres, and / or enhanced 
stimulation of efferent secretomotor nerves. Finally, the end organs (i.e. the 
glands and the vasculature) may themselves be altered to respond more 
vigorously to neural or direct stimulation (Togias A, 2000).
In studies performed in the supervising laboratory, it has been shown that nasal 
allergen challenge leads to increased hyper responsiveness of nerves (Sheahan P,
2005) (Sheahan P, 2006).
1 . 1 2  M o l e c u l a r  p a t h o p h y s i o l o g y  o f  a l l e r g i c  r h i n i t i s
A coordinated response of resident inflammatory cells, which play an 
immunomodulatory role, recruiting profession inflammatory cells and resident 
non inflammatory cells, are all involved in the pathogenesis of AR. In the most 
typical AR response, the mast cell is considered to play a pivotal role (Figure 1). 
The mast cell is resident in the nasal mucosa and is coated with (sometimes 
several) IgE antibodies bound to mast cells via various high and low affinity FcR 
receptors. Inhalation of allergen leads to contact between the allergen and the
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nasal mucosal mast cells. This recognition leads to activation of the mast cell and 
the release of substances, including histamine, leukotrienes, tryptase, and 
prostanoids and other fatty acid like molecules including lipoxins and sphingosine 
1 phosphatase.
These released mediators have direct effects on resident cells, including blood 
vessels, epithelial cells, nerves and mucous glands (Togias A, 2000). These 
released agents also are important in the recruitment of professional inflammatory 
cells which then may provide a second sustained inflammation.
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F ig u re  1.
F ig u re  1. M ast ce lls  in the lum en o f  a  patient with A R  is  shown. M ast ce lls  were  
identified  with an antibody to tryptase (red) a n d  nerves were identified  with an  
antibody to P G P 9 .5  (brow n). N ote the p resen ce  o f  m ast c e ll sta ining  in the lumen  
in the epithelium , m ucous g lands a n d  a round  the nerves. White arrow  ~  nerve, 
ye llo w  arrow  =  m ast c e ll adjacent to nerve, c irc le d  in  green. P ictu re  a n d  w ork by 
Thornton M a n d  C o ste llo  RW .
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Histamine is released locally by mast cell degranulation after nasal allergen 
challenge (Baroody FM, 1994), and has multiple effects on the nasal mucosa. It 
directly stimulates glands and blood vessels, leading to glandular secretion, 
plasma extravasation, vasodilation of the capacitance vessels and plasma 
exudation from the post-capillary venules of the subepithelial plexus. This leads 
to vascular congestion (Nathan RA, 2005 ).
Histamine also stimulates sensory nerves, leading to sneezing, itching, and reflex- 
mediated glandular secretion (Togias A, 2000) (Nathan RA, 2005 ).
These effects are abolished after nasal pre-treatment with HI receptor antagonists 
(Raphael GD, 1989) (Baroody FM, 1994). As a result, anti-histamine treatment is 
now central to the treatment of acute AR responses, indicating how important this 
mediator is in the pathogenesis of AR.
Leukotrienes
Leukotrienes released from mast cells also have strong effects on blood vessels, 
leading to nasal congestion (Widdecombe JG, 1990). Leukotriene receptor 
antagonists, such as montelukast are effective in preventing nasal obstruction due 
to natural allergen exposure (Philip G, 2002) (Okubo K, 2008), allergen challenge, 
and nasal mannitol challenge (Lee DK, 2003). Mannitol acts as a hyperosmolar 
stimulus causing nasal hyper-reactivity, as demonstrated by a reduction in nasal 
peak inspiratory flow after such a challenge.
H ista m in e
4 0
The role of leukotrienes in AR is well demonstrated, and while they have been 
shown to be effective both at inhibiting the mediator’s effects locally, they also 
prevent the recruitment of so called professional inflammatory cells by preventing
the upregulation of vascular adhesion molecules.
In addition, it has been shown that activation of leukotriene receptors results in 
increased electrical excitability of capsaicin-sensitive (presumably nociceptive) 
sensory neurons, which in turn mediate trigeminal nerve activity responsible for 
the initiation of sensations, such as itch. These neurons also mediate central 
reflexes such as sneezing, and increase in parasympathetic-mediated 
hypersecretion from the nasal mucosa. Similarly, the effects of histamine are 
potentiated by leukotrienes (Taylor-Clark TE, 2008). There is little evidence 
however, that these medications alone are sufficient to attenuate all the 
subsequent inflammatory changes that occur after exposure to an allergen.
Sphingosine 1 phosphate (SIP)
This bioactive lipid produced by mast cells and platelets is important in AR. 
Released rapidly after mast cell activation, SIP has been shown to act directly on 
mast cell-bound SIP receptors, leading to activation of the mast cell, and in 
particular, production of cytokines. In this laboratory it has recently been shown 
that SIP also acts on specific eosinophil SIP receptors, SIP1,2,3, and 5, and that 
some of these receptors are upregulated after allergen challenge. Furthermore 
eosinophil chemotaxis is significantly increased after the exposure to SIP, 
indicating that this mediator is important in the recruitment of other important
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inflammatory cells to the site of injury. SIP has also been shown to be important 
in the recruitment and retention of lymphocytes to specific sites of inflammation.
T-cells
In addition to releasing mediators which act directly on end-organs. mast cells 
also release cytokines, including IL-4, IL-5, IL-13, and TNF-a, which lead to the 
expression of adhesion molecules and chemo-attraction of inflammatory cells 
including T cells, in particular Th2 cells (Maezawa Y, 2004). Increased numbers 
of CD3-positive T cells in the nose have been reported in subjects with allergic 
rhinitis (Figure 2), particularly during times of allergen exposure (Wilson DR, 
2001) (Gluck J, 2005).
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F ig u re  2. C D -  p o sitive  T  ce lls  (sta ined red) in the nasa l m ucosa o f  a patient with  
persistent A R . Vascu lar a n d  n eu ra l d istribution  (brown stain with antibody to the 
nei-ve m arker P G P 9 .5 ), is shown. P ictu re  and  w ork by Thornton M  and  Costello  
RW .
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T cells may be activated directly after allergen exposure through antigen- 
presenting cells, including dendritic cells and eosinophils which are known to 
express MHC11 molecules (Godthelp T, 1996). T cells in turn recruit further 
inflammatory cells, including progenitor inflammatory cells to promote further 
local mast cells, eosinophils, and memory T cells. They also recruit T regulatory 
cells, which may limit the damage being done by these toxic inflammatory cells. 
All of this is mediated through the release of cytokines, including IL-3, IL-4, IL-5, 
and granulocyte/macrophage colony stimulating factor (GM-CSF).
The outcome of these events is a marked cellularity of the nasal airway, which is 
present within 6 to 24 hours after allergen challenge. This increased cellularity 
may be accompanied by a recrudescence of symptoms at 8 to 12 hours after 
challenge (Togias A 2000).
Eosinophils, neutrophils, and T-lymphocytes are all present in the late-phase 
cellular response, which is accompanied by release of eosinophilic cationic 
protein (ECP) and generation of myeloperoxidase (MPO) and leukotriene-B4 
(Miadonna A, 1999). The presence of these inflammatory cells and their products 
may be a factor in rendering the nasal tissues more responsive to subsequent 
challenge with a smaller amount of allergen, and this is the so-called “priming 
effect” (Skoner DP, 2001). Nasal tissue may become more responsive to their 
own inflammatory cell products (e.g. histamine) (Togias A, 2000), and this is the 
so-called “hyper responsiveness” of the nose.
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The eosinophil is pivotal in the pathophysiology of chronic nasal inflammation 
(Kramer MF, 2004), and is believed to play an important role in the late phase of 
the allergic reaction. Increased numbers of eosinophils in nasal submucosa and 
epithelium are seen in allergic rhinitis following both natural allergen exposure 
(Bentley AM, 1992) (Wilson SJ, 1998) and experimental allergen challenge 
(Miadonna A, 1999). This process is believed to be regulated, at least in part, by 
TH-lymphocytes, with elevated eosinophil cationic protein (ECP) levels found in 
T helper lymphocyte type 2 (atopic) diseases such as allergic asthma and allergic 
rhinitis but also occasionally in other diseases such as bacterial sinusitis (Bystrom 
J 2011 ).
The most prominent feature of the eosinophils are their large secondary granules, 
each containing four basic proteins, the best known being the eosinophil cationic 
protein. This protein has been developed as a marker for eosinophilic disease and 
quantified in biological fluids including serum, bronchoalveolar lavage and nasal 
secretions (Bystrom J 2011 ).
Eosinophil recruitment is associated with increased release of eosinophil products, 
including major basic protein (MBP) (Figure 3), and the previously mentioned 
eosinophil cationic protein (Wilson SJ, 1998) (Miadonna A, 1999). These granule 
proteins are toxic when applied in vivo and in vitro to cells. In the lower airways 
the release of cationic proteins from eosinophils has also been suggested to be 
damaging to airway epithelium. However, this has not been demonstrated in the
1.13 The eosinophil in AR
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nose. Hence, other possibilities as to what eosinophils may be doing in the nasal 
mucosa of patients with AR have been investigated, in particular in functional 
studies in this laboratory. These data are outlined below.
In the lower airways, localization of eosinophils around airway nerves has been 
demonstrated in the lungs of allergen-challenged guinea-pigs, as well as in 
humans dying from fatal asthma (Costello RW, 1997). Thornton et al 
(unpublished) showed that this occurs during the late-phase allergic response of 
allergic rhinitis. The mechanisms for this localization are incompletely understood. 
However, primary cultures of airway parasympathetic neurons express the 
adhesion molecules intracellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1). Eosinophils bind to these molecules (Sawatzky 
DA, 2002). Airway neurons also express eotaxin. This eosinophil chemo- 
attractant eotaxin may be a mechanism whereby eosinophils are recruited to 
nerves (Fryer AD, 2006). Furthermore, co-culture of eosinophils with nerves 
significantly increased release of eosinophil peroxidase (EPO) and leukotriene C4 , 
compared to culture of eosinophils alone (Kingham PJ, 2002). There is evidence 
that the interaction of eosinophils with cholinergic nerves in the lower airways 
may upregulate neural function, so leading to airway hyper responsiveness in 
asthma.
Muscarinic M2  receptors are inhibitory autoreceptors that are present pre- 
junctionally on postganglionic parasympathetic nerves. They are activated by
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acetylcholine, released from postganglionic nerves, and act to inhibit further 
acetylcholine release (Minette PA, 1988) (Costello RW, 1997). Loss of M2 
receptor function may occur during the late phase of the allergic reaction as a 
result of the actions of eosinophil products, such as eosinophil major basic protein 
(MBP, see Figure 3), which has been shown to be an allosteric inhibitor of M2 
receptors (Jacoby DB, 1993) (Jacoby DB, 2001). In sensitised guinea-pigs, loss of 
M2 receptor function, accompanied by hyper responsiveness to electrical 
stimulation of the vagus nerve, is seen 24 hours after allergen challenge. This loss 
of M2 receptor function and airway hyper responsiveness is prevented by pre­
treatment with antibody to MBP (Evans CM, 1997). In humans, inhalation of 
pilocarpine, an M2 receptor agonist, inhibits vagally mediated reflex 
bronchoconstriction after inhalation of sulphur dioxide in normal subjects, but not 
in subjects with atopic asthma, suggesting that loss of M2 receptor function also 
occurs in humans as a result of allergic inflammation (Minette PA, 1989).
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CHAPTER 2 - ACID SENSING ION CHANNELS
Acid sensing ion channels, ASICs, are a family of ligand-gated cation channels, 
activated by acid (pH <7.4 -  pH 5.5) (Waldmann R, 1998), (Sutherland SP, 2001), 
(Gu Q, 2006). Previously, they were referred to as dorsal root acid sensing ion 
channels (DRASIC) (Sluka KA, 2004). They belong to the amiloride-sensitive 
degenerin/epithelial Na+ channel (ENaC) superfamily (Figure 4) (Waldmann R,
1998) (Kellenberger S, 2002) (Wemmie JA, 2006) (Xu TL, 2007). H+-gated 
cation channels are the only ion channels known to be directly activated by a pH 
change (Waldmann R, 1997) and to date, the only known activators of ASICs are 
protons (Waldmann R, 1998)(Xu TL, 2007). With regards to other ion channels 
which are gated by physical or chemical conditions other than changes in pH, 
proton-gated ion channels use protonation for activating an ionic current (Reeh 
PW, 2001).
Since this novel amiloride-sensitive sodium channel was first isolated and cloned 
in 1995 (Waldmann R, 1995), and the proton-gated cation channel cloned 
(Waldmann R, 1997), at least six subunits of ASICs have been identified; ASIC1 
with its two isoforms la (Waldmann R, 1997) and lb (Chen CC, 1998), ASIC2 
with its two isoforms 2a (Price MP, 1996), localized to the cerebellum (Jovov B,
2003), and 2b (Lingueglia E, 1997), ASIC3 (Babinski K, 1999) and ASIC4 
(Grunder S, 2000) (Krishtal 2003). A role for ASIC4 has not been determined but 
it may be involved in downregulation of ASIC3 (Donier E, 2008). A further 
isoform, ASIClb2 has since been additionally identified (Deval E, 2008). All but
2.1 Acid-sensing ion channels (ASIC); structure and function
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two of these subunits, ASIC2b and ASIC4, have so far been shown to be activated 
by protons, and this is true for mammalian cases (Donier E, 2008). Of the rest of 
the isoforms, ASIC-3 is the most proton-sensitive, and opens when pH drops from
7.4 to 7.0 (Immke DC, 2003). However, initial earlier reports by Babinski et al 
suggested as low a pH as 4 to cause ASIC-3 activation (Babinski K, 1999). ASIC- 
1 and ASIC-2 channels have been reported to activate at a pH at or below 5 (de la 
Rosa DA, 2002)
The distribution of ASICs varies in different cells and under different 
physiological conditions, and they may function at various subcellular locations. 
The majority of studies have featured their location and roles in the brain, 
synapses, and throughout dorsal root ganglia of the peripheral nervous system 
(Waldmann R, 1997) (Reeh PW, 2001). Their presence in dorsal root ganglia 
corresponds to their function as acid sensors in nociception, but their role in the 
brain is as yet unclear (Waldmann R, 1997). They have also been shown to occur 
in epithelial tissues, such as kidney, colon, testis, ovary, pituitary, heart and lung 
(Waldmann R 1995) (Babinski K, 1999) (Groth M, 2006) (Yiangou Y, 2001).
Stimulation of these receptors on nerves leads to a variety of sensations including 
pain and mechanoperception, while epithelial expression is linked to airway 
secretion and has been reported in cystic fibrosis cell lines (Su X, 2006). Other 
functions include taste transduction (particularly sour taste), synaptic plasticity, 
learning / memory, acid-mediated neuronal injury, and even cochlear function
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(Xu TL, 2007) (Donier E, 2008). Increasing evidence would purport a role for 
these receptors in neurological diseases, brain ischaemia and epileptic seizures 
(Xiong ZG, 2008). A description and function of these receptors in human upper 
airways has not yet been described.
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Each ASIC subunit consists of two transmembrane domains, TM I and TM II 
(Xiong ZG, 2008) (see Figure 5). These are connected by an extracellular cystein- 
rich loop and intracellular N and C termini (Waldmann R, 1998). These are then 
assembled as tetramers of homomeric or heteromeric subunits (Lingueglia E,
1997) (Bassilana F, 1997) (Krishtal, 2003) to form amiloride-blockablc proton- 
activated cation channels in the mammalian central and peripheral nervous 
systems (Ugawa S, 2005). Our interest is primarily in the structure and function 
of ASIC-3, whose mRNA encodes 531 amino acids, with a molecular mass of 
59kDa (Babinski K, 1999).
2.2 Structure of ASICs
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F ig u re  5. Structure o f  A S I C  subunit. A  s in g le  subunit com prises 2 transm em brane  
dom ains (TM 1 a n d  TM 2), an e xtra ce llu la r loop responsib le  f o r  gating, and  an 
in tra ce llu la r term ini. F o u r  subunits are assem bled  in the m embrane to fo rm  a 
fu n c tio n a l unit (F ig u re  4). A d a p ted fro m  K r is h ta l O, 2003.
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2 . 3  A c t i v a t i o n  o f  A S I C s .
Extracellular protons activate ASICs to affect neuron function (Wemmie JA,
2006), through the simplest fonn of ligand binding (Reeh PW, 2001). Small to 
moderate changes in pH are sufficient for ASICs to respond, such as occurs 
during tissue inflammation (Xu TL, 2007), with ASIC-3 having a very steep 
activation curve (Sutherland SP, 2001). Activation however occurs only when 
accompanied by rapid pH drops but transient opening of ASICs can generate a 
long lasting effect, potentially by being modulated by other signalling molecules 
such as lactic acid (Xu TL, 2007). Studies have shown that ASICs are responsible 
for pain perception at a pH >6.0. As alluded to previously, ASIC-3 channels open 
with a pH drop from 7.4 to 7.0 (Krishtal 2003) (Immke DC, 2003), whereas other 
ASICs are less sensitive to acidity (Sutherland SP, 2001). Ugawa et al suggests 
ASICs are activated at a pH of 7.2 to 6.0 (Ugawa S, 2002). Contrasting earlier 
reports however, suggest a pH value as low as less than 4 for ASIC3 currents to 
be activated to cause mechanical hyperalgesia (Waldmann R, 1998) (Babinski K,
1999) (Sluka KA, 2004). Some reports suggest ASIC1 channels open at a pH of
6.9 (Waldmann R, 1997), whilst others quote figures of pH 5 and below (de la 
Rosa DA, 2002).
2 . 4  R o l e  o f  A S I C s
Although a variety of functions have been attributed to ASICs, there is still 
controversy about their actual functions in mammals (Reeh PW, 2001). They are 
thought to play a role in nociception (Waldmann R 1997) (Voilley N, 2001), with
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studies suggesting that they modulate the perception of moderate to high-intensity 
acid-induced pain sensation (Chen CC, 2002). A positive correlation between pain 
and tissue acidity has been shown previously (Deval E 2008). The presence of 
ASICs, primarily in small-diameter and small-medium diameter sensory neurons, 
supports their involvement in these nociceptor pathways and contributes to the 
pH-sensitivity of nociceptors (Yiangou Y, 2001) (Ugawa S, 2005). Furthermore, 
it appears that hyperalgesia is primarily modulated by the presence of ASIC-3 in 
particular, and seems to be independent of the presence of ASIC-1 (Sluka KA,
2004). In fact, loss of ASIC-3 causes reduced responsiveness to acid (Price MP, 
2001).
It is clear, through their expression throughout the peripheral and central nervous 
system, that ASICs have a role in signal transduction or in maintenance of cellular 
function (Reeh PW, 2001). Local peripheral inhibition of these receptors by 
ASICs antagonist amiloride has been shown to reduce nociceptive behavior in 
mouse experiments, from an ipsilateral but not contralateral perspective (Rocha- 
Gonzalez HI, 2009). Despite this, to date, it is unclear to what extent the cloned 
proton-sensitive ion channels contribute to pH-responses in nociception (Reeh 
PW, 2001).
Other receptors, such as the capsaicin receptor, transient vanilloid receptor 
subtype (TRPV1), also appear to modulate pain through proton responses, but 
among unmyelinated fibres, whilst there is a suggestion that ASIC subunits play 
more of a role in thin myelinated nociceptors (Leffler A, 2006). Similarly, Ugawa
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et al suggests that ASICs play a bigger role in nociception at a pH of 7.2 to 6.0, 
whereas TRPV1 channels do not start to open till a pH of less than 6.0 is reached 
(Ugawa S, 2002)
ASICs also play a role in sensory and mechanoperception (Price MP, 2001). The 
suggestion that ASICs has a role in pilocarpine-induced limbic seizures and status 
epilepticus has also been studied, using the ASICs inhibitor amiloride as a 
potential anticonvulsant (N'Gouemo, 2008).
Interestingly, in epithelial cells ASIC-3 has been co-immunoprecipitated with the 
cystic fibrosis transmembrane receptor (CFTR) where their function in epithelial 
cells has been suggested to be involved in the maintenance of airway hydration 
(Su X 2006). Tissue acidification, which occurs during conditions such as 
inflammation and ischaemia, activates acid-sensitive ion channels. The 
condensate from the exhaled breath of both asthma and rhinitis patients is more 
acidic than that of healthy controls (Ojoo JC 2005 ). Hence, there may be 
increased activity of ASIC in a chronic inflammatory condition such as AR.
Ultimately, only inactivation of ASIC genes in animal models will perhaps clarify 
the physiological roles of ASICs in the central and peripheral nervous systems 
(Kellenberger S 2002).
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2 . 5  L a c t i c  a c i d  a n d  i t s  e f f e c t  o n  a c i d - s e n s i n g  i o n  c h a n n e l s
In response to reduced oxygen supply, lactic acid is produced during 
inflammation and ischaemia by enhancement from aerobic to anaerobic 
metabolism of glucose and the release of H+ from ATP hydrolysis (Xu TL 2007) 
(Xiong ZG 2008). This causes a reduction in tissue pH, termed acidosis.
Lactic acid acts through chelating extracellular divalent ions such as calcium and 
magnesium (Xu TL 2007), decreasing them and thus increasing activity of ASICs 
(Immlce DC 2001). These divalent ions have a significant role to play in 
modulating ASIC-3 function, whereby decreasing calcium opens the ASIC-3 
channel, altering calcium shifts pH-dependent gating, and raising calcium blocks 
the channel (Immke DC, 2003). Immke & McCleskey also showed that 
decreasing extracellular pH to 7, in the presence of 15mM of lactic acid, 
depolarised ASICs-associated neurons about 70% more than at pH 7 alone 
(Immke DC 2001). Its effects were apparent in both ASIC-3 and ASICla 
receptors. At higher pH levels of 7.4 to 8, lactic acid caused no depolarisations of 
neurons, suggesting that it acts by modulating but not activating ASICs (Immke 
DC 2001).
2 . 6  A S I C s  a n t a g o n i s m  b y  a m i l o r i d e
Amiloride has been used clinically as a diuretic since 1967 (Arias RL, 2008), and 
is a potassium-sparing diuretic. It works primarily by inhibiting the epithelial 
sodium channel (ENaC) of the renal tubules (Arias RL, 2008), and is also a non-
selective blocker of ASICs (Krishtal 2003) (Hayes SG, 2007) (Arias RL, 2008) 
(Rocha-Gonzalez HI, 2009). It is this character that allows it to be used as a 
pharmacological tool to identify ASIC receptors (Xu TL 2007). As alluded to 
previously, ASICs are activated by acidic pH, and the inhibitory effects of 
amiloride are specific for acid-induced pain (Jones NG, 2004). In fact, injection of 
amiloride appears to significantly attenuate acid-mediated pain, suggesting that 
amiloride-sensitive ASIC channels are responsible for a substantial proportion of 
acid pain (Jones NG, 2004).
Despite it being non-specific, it has been shown that higher concentrations are 
required to inhibit ASIC3 receptors as opposed to ASIC la, ASIC lb, and ASIC2a 
subunits (Lingueglia E 1997) (Bassilana F 1997). The sustained component of 
ASIC depolarisation current is certainly less responsive to amiloride (Waldmann 
R 1997).
2 . 7  A S I C s  i n  r e s p i r a t o r y  m u c o s a
It is known that proton-activated channels similar to ASIC, known as transient 
receptor potential vanilloid receptor subtype-1 (TRPV1) receptors, occur in lung 
and nasal mucosa, and it is postulated that they play a role in cough and pain 
sensation. TRPV1 has been expressed and localized to vascular endothelial cells, 
submucosal glands, and nerves in human nasal mucosa, and in fact appears to also 
have a role in secretory functions (Seki N, 2006). Almost all mammalian 
nociceptive C-fibre neurons express TRPV1 channels (Taylor-Clark TE, 2008).
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The receptor for TRPV1 channels is capsaicin, the pungent component in chili 
peppers (Taylor-Clark TE, 2008).
Apart from capsaicin, TRPV1 is activated by heat and protons, and acts as a 
primary sensor to chemical and physical stimuli that cause pain (Tominaga M
1998). However, whilst initial application of capsaicin to human nasal mucosa 
was found to produce a painful response as expected, further repeated applications 
caused a marked attenuation of pain, demonstrating a characteristic 
desensitization of the nasal mucosa (Geppetti P, 1993). Stjame in 1998 showed 
that topical application of capsaicin, as a desensitizing antagonist of TRPV1, to 
the nasal lining mucosa of patients with allergic rhinitis caused relief of nasal 
symptoms (Stjame P 1998). Both TRPV1 and ASIC3 have also been shown to 
occur in dorsal root ganglia that project to lung and pleura mucosa of rats (Groth 
M 2006) (Su X 2006). It is therefore fair to postulate that, with TRPV1 expressed 
in nasal mucosa, similarly ASIC3 may also be expressed in nasal mucosa, and 
play a role in patients with allergic rhinitis. The similarities between lung and 
nasal epithelium add further weight to this. In experiments in both mice and rats 
however, there were marked species differences in expression of TRPV1 and 
ASIC and marked differences even within subpopulations of sensory neurons 
(Leffler A, 2006). Rat vagal pulmonary sensory neurons have been shown to be 
activated by a lower pH of between 7 and 5.5 (Gu Q, 2006). The same cannot, 
therefore, be extrapolated directly to humans.
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Increased nasal secretion and higher nasal discharge scores have been noted 
following application of saline, which is an acidic media, in the nose (Barannik 
JN, 2002) (Pinto JM, 2006). In the same way increased nasal secretions occur 
after swimming in acidic sea water, we postulate that acid-sensing ion channels, 
among other factors, play a role in modulating nasal secretion in this instance. 
ASICs have been identified in various sites of the body, including the lung. They 
have not been shown to be present in nasal mucosa. With striking similarities 
between lung and nasal mucosa, we postulate that ASICs occur in the nasal 
epithelia and glands, and are upregulated in patients in whom increased nasal 
secretion is characteristic, such as in allergic rhinitis.
We hypothesized that ASIC-3 is the functioning receptor in nasal mucosa, and 
this receptor would be blocked by ASIC inhibitor, amiloride, and would be 
functional at an acidic environment and a pH of 7.0.
With evidence of neural responses at work within the nasal cavity, causing 
contralateral responses in the opposite nasal cavity to that exposed to challenge 
substances, we hypothesized that ASIC-3 is intimately related and co-localised to 
neural structures and nerve bundles.
We also hypothesized that the eosinophil has a major role to play in inflammatory 
conditions such as allergic rhinitis, and may have a part to play in acting via ASIC 
receptors or inducing them or mediating them to react.
2.8 Hypothesis
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C H A P T E R  3 -  M A T E R I A L S  A N D  M E T H O D S
3 . 1  B e a u m o n t  H o s p i t a l  S c i e n t i f i c  C o m m i t t e e  e t h i c a l  a p p r o v a l
Ethical approval for this project was sought from the Scientific Committee Ethics 
Department at Beaumont Hospital, where the study was undertaken, on 14 August 
2007. Final approval was obtained on 15 October 2007, reference 07/65 (see 
Appendix 1.)
3 . 2  P a t i e n t  s e l e c t i o n .
Patients were recruited into an AR Study group and a Control group, and were 
age and sex matched.
Criteria for inclusion into the study group was based on the symptoms and 
diagnosis of persistent allergic rhinitis as per the “Allergic Rhinitis and Its Impact 
on Asthma” (ARIA) criteria (Bousquet J, 2001). This defines allergic rhinitis as a 
symptomatic disorder of the nose after allergen exposure by an immunoglobulin E 
(IgE)-mediated inflammation of the membranes. Only patients with persistent 
allergic rhinitis based on the ARIA classification were included in the study group, 
(see Table 1). Skin prick tests were undertaken to confirm the allergic nature of 
each patient’s rhinitis. The method of skin prick testing is detailed in Section 3.5.
Patients with intermittent allergic rhinitis, out of season, were omitted. Excluded 
were minors below the age of consent, cognitively impaired patients, and patients 
greater than 65 years of age. Any patient unable to understand and sign informed 
consent was also excluded. Women who were pregnant or breastfeeding were 
excluded, as were patients with a history of anaphylaxis. Patients on aspirin,
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warfarin or plavix, or any other “blood thinners” were excluded, based on the fact 
that nasal biopsies were to be taken, thereby increasing the risk of epistaxis post­
procedure. Patients with any other nasal pathology such as granulomatous
diseases or malignant disease were also excluded.
Criteria for inclusion in the Control group was based on no symptoms, past or 
present, of nasal blockage, constant nasal secretion, and any history of atopy.
Recruitment of patients was undertaken primarily from the general Ear Nose and 
Throat clinics, Respiratory Allergy clinics and specialised Rhinology clinics, with 
the principal investigator approaching these participants in person. Further 
recruitment was undertaken via posters alerting the general public about the 
commencement and nature of the study, and these were prominently displayed 
around the host hospital.
Following recruitment of each participant, a full description of the reason for the 
project and a clear explanation of what the study entailed was related to the 
participant and both written and informed consent obtained. Each participant was 
given an information leaflet detailing the study for their perusal at their own time, 
prior to agreeing to the study. Participants were encouraged to take the leaflets 
home with them to study, prior to contacting the principal investigator with a 
decision as to whether they wished to participate in the study or not.
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T a b le  1 In c lu s io n  / e x c lu s io n  c r ite r ia  fo r  e n ro lm e n t in to  the  A lle r g ie  R h in it is
Study group
I n c l u s i o n  c r i t e r i a E x c l u s i o n  c r i t e r i a
Patients with persistent allergic rhinitis Minors below the age of consent
Cognitively impaired patients
Patients greater than 65 years of age
Any patient unable to understand and sign 
informed consent
Women who are pregnant or breastfeeding
Patients with a history of anaphylaxis
Patients on aspirin, warfarin or plavix, or any 
other blood thinners
Patients with any other nasal pathology such 
as granulomatous diseases or malignant 
disease
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• Diagnostic skin prick allergens - Allerayde Ireland Limited, Blackrock, 
County Dublin
• Skin prick test lancets - Allergopharma Joachim Ganzer KG
• 1% hydrocortisone cream - Hydrocortisyl Skin Cream 1%, Aventis, 
Dublin, Ireland
• Cottles nasal speculum
• ‘Crocodile’ microforceps
• Blakesley 45 degree upward cutting upped biopsy forceps -  Explorent 
GMBH
• Co-phenylcaine nasal spray (lignoeaine hydrochloride 5% and 
phenylephrine) -  Medisource, Dublin, Ireland
• Filter paper collection discs - Shandon Inc, Pittsburgh USA
• NUNC ciyotube vials -  Bio-Sciences, Dun Laoghaire, County Dublin, 
Ireland
• Dilvac liquid nitrogen flask -  Dewar, Wolfe Laboratories, UK
• Polypropylene pellet pestle — Sigma Aldrich, USA
• DNA Engine PCR thermal cycler -  Roche, USA
• pH/°C meter - Eutech EcoScan BNC Lenox, Drogheda, Ireland
• Leica DF350 FX digital camera, Leica, Milton Keynes, UK
3.3 General materials
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Clinical experiments
• Amiloride hydrochloride hydrate
• Alkaline sodium hydroxide 98% buffer
• 2M alkaline buffer - sodium hydroxide 98%
All Sigma, Poole, UK
• Lactic acid free acid - Sigma Aldrich, Ireland
• Isotonic saline solution - 0.9% sodium chloride injection, Braun Medical 
Ltd, Dublin Ireland
PCR
• RNeasy mini kit
• QuantiTect reverse transcription kit
• QuantiTect SYBR Green PCR kit
• RNALater RNA stabilization reagent 
AU Qiagen, Hilden, Germany
• ASIC 1,2,3 primers
• AS1C3 antibody
• Rabbit polyclonal antibody to ASIC3 
All Abeam, Cambridge, UK
3.4 Reagent materials
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• Beta-mercaptoethanol
• 74% formaldehyde
• 0% ethanol
All Sigma, Poole, UK
• Wizard PCR Preps DNA Purification System -  Promega, Madison, WI, 
USA.
IMR-32 Cell cultures
P ro life ra tio n  M edium :
• Dulbecco's Modified Eagles Medium with Glutamax
• 5% Foetal Calf Serum (FCS) (25 mL)
• 1 % penicillin-streptomycin (5 mL)
All - GIBCO® Invitrogen (Paisley, UK).
• lul/ml gentamicin (0.5 mL) -  Sigma, Poole, UK
D ifferentiation  M edium :
• Dulbecco's Modified Eagles Medium with Glutamax
• 1 % penicillin-streptomycin (5 mL)
• 2% FCS (10 mL)
All from GIBCO® Invitrogen (Paisley, UK).
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• mM sodium butyrate (0.11 g)
• 1 ul/ml gentamicin (0.5 mL) -  Sigma, Poole, UK
Eosinophil peroxidase in co-culture with 16HBE14o cells.
• Eosinophil peroxidase (EPO) -  kindly donated by Dr Gerald Gleich, Utah, 
USA
• CuFi-1 cells - kindly donated by Prof Zabner, University of Iowa, USA.
• SV40-transformed human bronchial epithelial cell line 16IIBE14o -  
kindly donated by Dr Dieter Grunert, University of Vermont, USA
• Minimal essential medium (MEM)
• 10% FCS,
• 1 % L-glutamine
• 1% penicillin/streptomycin.
All from GIBCO® Invitrogen (Paisley, UK).
Western Blotting
All reagents from Sigma, Poole, UK unless specified.
• Acrylamide
• Tris buffered saline
• SDW -  sterile distilled water
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• SDS -  Sodium dodecyl sulphate
• APS -  ammonium persulphate
• TEMED -  Tetrainethylethylenediamine
• B- mercaptoethanol
• Tween 20
• PBS -  phosphate buffered saline.
1 0 %  Sep a ra tin g  Gel. S D S  Sam ple Treatm ent
B uffer
Acrylamide - 3.3 mL 1M Tris (pH 6.8) - lmL
SDW -3.9 mL 10% SDS -  2mL
1.5 M Tris (pH 8.8) -2.5 mL 0.1% Bromophenol Blue
200j.iL
10% SDS 200|iL dH?0 -  5mL
10% APS (O.lgimL) -  67pL Glycerol -  2mL
TEMED - 6.7|iL P -  mercaptoethanol — 1 mL
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Acrylamide - 500(.iL
dH20 -2.25 mL
0.5 M Tris (pH 6.8) -950pL
10% SDS -38|iL 
10% APS -25|iL 
TEMED -3.8nL
Transfer B u ffer I X
Tris -  2.42g
Glycine -  11.26g
10% SDS — lmL
Made up to 200 mL in methanol,
Add 800mL SDW.
W ashing B u ffer  
1 sachet PBS 
1 L SDW 
Tween 20 -  lmL
4 %  S t a c k i n g  G e l
Tris - 7.5g
Glycine -  36g 
SDS -  25g
Made up to 500mL in SDW
B lo c k in g  B uffer  
0.2g I-Block 
PBS -  lOOmL 
0.1% Tween 20- 100|iL
R u n n i n g  B u f f e r  5 X
A ssa y  B u ffer
SDW -  18mL
10X Assay Buffer -  2mL
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S u b s t r a t e / B l o t 1  O X  A s s a y  B u f f e r
CDP-Star -  1.9ml 200mM Tris-HCL pH 9.8
Nitro Block -  100|iL lOmM MgCl2
Immunohistochemical staining
• 5|j,m formalin-fixed, paraffin-embedded (FFPE) tissue sections
• Polyclonal antibody to ASIC-3 (1:50)- Abeam, Cambridge, UK
• Monoclonal antibody to PGP9.5 (1:50) - Novocastra, Newcastle-upon 
Tyne, UK).
• Km Tris-EDTA (Sigma-Aldrich; pH 9.0)
• Peroxidase-labeled Envision anti-rabbit or anti-mouse secondary 
antibodies -  Dako, Hamburg, Germany.
• Goat anti-rabbit Alexa-488 and goat anti-mouse Alexa-568 (both 1:500) -  
Invitrogen, Renfrew, UK.
• 4,6-diamidino-2- phenylindole Vectashield - Vector Laboratories, Inc., 
Dublin, Ireland.
3 . 5  D i a g n o s t i c  s k i n  p r i c k  a l l e r g y  t e s t s
Diagnosis of allergen-specific persistent allergic rhinitis was confirmed with 
diagnostic skin prick tests. These work on the basis that IgE antibodies that 
recognize specific allergens are triggered by mast cells when exposed to these 
antigens, resulting in an allergic wheal and flare reaction.
• TBS
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Nineteen different common allergens were purchased in droplet form, in addition 
to skin prick lancets and hydrocortisone cream to dampen down any wheal and 
flare reaction obtained. Specific skin test mixtures are documented in Table 2.
If any participants were taking antihistamines prior to skin prick testing, these 
were omitted at least three days before the test. This was based on evidence 
suggesting that up to 10-50% of negative skin prick test results may be due to 
antihistamine usage (dos Santos RV, 2009). Each participant was initially 
interviewed as to whether they had a history, or a family history of any 
anaphylactic / severe allergic reactions previously. Only those who answered 
negatively were considered for the study. All skin prick tests were carried out in 
the ENT clinic, with availability of resuscitation equipment at hand.
Each participant’s forearm was initially cleaned with 3 alcohol swabs. Each 
forearm was then delineated and prepared into three rows, allowing six skin 
pricks in two rows and seven skin pricks in the third. Nineteen clearly marked 
allergens were placed on the forearm and the skin epidermis beneath each drop 
was pricked with a lancet needle to allow exposure to specific allergens. As just 
the very surface of the skin is pricked, these were painless, and just enough to let 
a tiny amount of solution into the skin. A reaction was deemed to be positive, and 
allergy determined, when a wheal and flare reaction comparable to that obtained 
with the positive histamine skin prick developed following allergen exposure after
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fifteen minutes. These results were duly recorded. Hydrocortisone 1% cream was 
spread onto the forearm to dampen down any positive inflammatory wheal and 
flare reactions obtained on completion of the skin prick test. Participants were 
encouraged to stay within the vicinity of the ENT clinic for 15 minutes after the 
procedure to ensure no adverse reactions. There were no recorded anaphylactic 
reactions or complications in any of the participants.
Table 2. Diagnostic skin prick test allergens.
Positive control (histamine) Aspergillus fumigatus
Negative control (glycerol-saline) Altemaria tenuis (A. alternata)
Dermatophagoides pteronyssinus Pénicillium notatum
Dermatophagoides farinae Candida albicans
Dog hair Duck feathers
Cat hair Goose feathers
Horse hair Wheat flour
Grass mix Cow’s milk
Tree mix (early blossoming) Hen’s egg (whole)
Cladasporium herbarum
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3 . 6  P h y s i o l o g i c a l  n a s a l  s e c r e t i o n  c o l l e c t i o n  a n d  n a s a l  c h a l l e n g e  w i t h  
i s o t o n i c  s a l i n e  a n d  a m i l o r i d e
Nasal secretions may be collected via a number of different techniques. This can 
be through spontaneous secretion, dilution techniques, or absorption techniques 
(Riechelmann H, 2003) (Nathan RA, 2005 ). To most accurately obtain sufficient 
secretion for analysis, either dilution techniques or absorption techniques may be 
undertaken and are the most appropriate.
Dilution techniques include nasal lavage, with collection of the returned fluid 
(Raphael GD, 1989) (Austin CE, 1994 ) (Turner PJ, 2000). Absorption techniques 
can be performed via the placement of filter paper collection discs onto the nasal 
mucosa, which absorb nasal secretions directly (Baroody FM, 1993) (Riccio MM, 
1996) (Sanico AM, 1999 ) (Sheahan P, 2005). For studies requiring assessment of 
the actual constituents of the secretion obtained, sampling with a polyurethane 
foam sampler technique is considered most useful (Riechelmann H, 2003).
As we were only measuring the weight of the nasal secretions, we used the 
absorption technique, in which pre-weighed, dry collection discs made from thick 
filter paper (Shandon, Pittsburgh, USA) were placed for a given period of time 
onto the anterior nasal septum. A 6mm paper punch was used to ensure that the 
discs were of uniform size and shape, so that they contacted a similar area of nasal 
mucosa on each occasion (Sheahan P, 2005). Discs were weighed using a 
laboratory TR208 weighing scale, accurate to 0.000 lg.
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Nasal secretions are absorbed from the area of mucosa with which the discs are in 
contact (Baroody FM, 1993) (Sheahan P, 2005). The use of thick filter paper discs 
was essential in order for the discs to have sufficient capacity to absorb large 
secretion volumes. The discs we used could absorb 40microL of fluid (Sheahan P,
2005). The filter paper disc technique thus allows measurement of nasal secretion 
weights, which can be calculated by subtracting the dry weight of the collection 
discs before placement into the nose, from the weight obtained after removal. A 
major advantage of this technique is that it allows secretions to be collected from 
both the ipsilateral and the contralateral side to the unilateral provocation, and 
thus allowing neurally mediated outcomes involving central reflexes to be 
assessed (Nathan RA, 2005 ). In contrast, secretion weights or volumes cannot be 
reliably measured using nasal lavage. The filter paper disc technique also has the 
advantage of being considerably better tolerated by volunteers.
All filter discs were initially pre-weighed to ascertain their baseline weights at 
‘Time=0’. Two discs were then placed on the anterior nasal septum of both nasal 
cavities following nasal challenge (described in the following section) for 2 
minutes (Time = 2 minutes) and 5 minutes (Time = 5 minutes), see Figure 6. 
These were weighed subsequently, and their baseline weights were subtracted 
from their measurements to equate to nasal secretion weight.
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F ig u re  6.
Nasal septum
Disc = weight pre-measured. 
Baseline, Time =0
Secretions collected 
Time = 2 minutes
Secretions collected 
Time = 5 minutes
Secretions collected 
Time = 2 minutes
Secretions collected 
Time = 5 minutes
F ig u r e  6. Stru ctu ra l design o f  c lin ic a l p h y s io lo g ica l n a sa l secretion weight 
co llections. Sta n d a rd ised  absorbab le  f i lt e r  d iscs w ere a p p lie d  to the anterior  
septum  in  both n a sa l cavities f o r  2 m inutes a n d  5 minutes.
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Nasal challenge may be performed either by administration of the challenge 
substance into the nasal cavity by means of a nasal spray (Hofmann T, 1998) 
(Rodgers HC, 1999) (Turner PJ, 2000), or by placement of a filter paper disc 
containing a solution of the challenge substance in contact with the nasal mucosa 
(Baroody FM, 1993) (Riccio MM, 1996). The challenge substance then diffuses 
from the filter paper disc onto the nasal mucosa.
The use of a filter paper disc for nasal challenges can be advantageous, in the 
sense that a reproducible dose of the challenge substance may be administered on 
every occasion. Discs used must be of uniform size and shape, and contain a 
known quantity of the challenging substance. They must also be left in contact 
with the nasal mucosa for a uniform period of time, and if performed accurately, 
this technique of nasal challenge has been shown to lead to reproducible secretory 
responses (Baroody FM, 1993). However, the amount of challenge substance that 
elutes off the filter paper disc onto the nasal mucosa is unknown, and therefore, 
the use of nasal sprays can be equally advantageous, if the correct number of 
sprays is uniformly used on all occasions. We used the latter technique to good 
effect.
Each nasal cavity was initially assessed for patency using a Cottles nasal 
speculum and a headlight. This was to ensure that no marked septal deviation 
existed in the study participant that may prevent the challenge substance from 
reaching its intended target on the anterior nasal mucosa. Following assessment of
T e c h n iq u e  o f  n a sa l ch a lle n g e
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nasal patency in both nostrils, each spray was directed antero-superiorly and 
laterally. This targeted the nasal turbinates and anterior septum, to allow for 
accurate and standardised administration of the challenge substance in each and 
every case. It was accepted that there was always going to be the potential for 
variation in the amount of challenge substance delivered to the nasal mucosa not 
only between subjects, but also at different times within the same subject. This is 
due to variations in the degree of mucosal congestion, as may occur after allergen 
exposure in allergic subjects, or as part of the nasal cycle in normal or allergic 
subjects.
Two different solutions were used to promote nasal secretory response, using 
isotonic saline solution and buffered lactic acid in the form of aerosol sprays. 
Measurement of secretory response to saline and lactic acid challenges was 
undertaken using filter paper discs placed in both nostrils. Discs were pre­
weighed in 5(j.L Eppendorf tubes and this constituted the baseline weight 
measurement
Isotonic saline solution was made up into an aerosol spray using pre-used co- 
phenylcaine bottles, with disposable nozzles. A pH measurement of the solution 
was obtained with the Eutech EcoScan pH/°C meter, which measured pH 5.5 
undiluted. Standardised isotonic solution was used for all experiments from the 
same bottle to ensure accurate pH measurements for all participants. Three sprays 
of this saline solution were applied to one nostril randomly selected before the 
procedure and allowed to absorb into the nasal mucosa.
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Following that, two fresh filter discs were placed in each nostril, once again on 
the anterior nasal septum just posterior to the nasal columella. Ipsilaleral and 
contralateral nasal secretions were collected over 2 minute and 5 minute durations, 
measuring the ipsilateral direct nasal secretory response, and the contralateral 
neural-mediated reflex response, see Figure 7. These measurements were then 
compared with the baseline nasal secretion weights.
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F ig u re  7.
Nasal septum
I PS I LATE RAL
Day 1
0.9% NaCI or Lactic acid
Secretions collected 
Time = 2 minutes
Secretions collected 
Time = 5 minutes
CONTRALATERAL
Secretions collected 
Time = 2 minutes
Secretions collected 
Time = 5 minutes
F ig u re  7. N a sa l secretion  w eight co llectio n s fo llo w in g  nasa l cha llenge with 
isotonic sa lin e  o r  la ctic  acid. T h is  w as c a rr ie d  out on D a y  1 o f  p h ys io lo g ica l 
experim ents, fo llo w e d  on D a y  2 by pretreatm ent with A S IC - in h ib ito r  am iloride.
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The following day, participants were invited back, and their nasal mucosa 
pretreated with amiloride spray. This was made up into an aerosol spray, diluted 
to Ixl0-3M solution, at its limit of solubility with sterile water. This was 
calculated using the formula weight of amiloride of 266.1g/L to make 1M and its 
solubility in water of 50mg/mL. Therefore, 0.266lmg/mL was required for 
dilution to Ixl0-3M, and lg of amiloride was added to 3.757L of water to ensure 
this dilution.
This was introduced to the same nasal cavity that was challenged with isotonic 
saline the previous day. Nasal challenge was once again instituted into the same 
nasal cavity (termed the ipsilateral side) with isotonic saline, half an hour after 
amiloride pre-treatment, and weight collections at 2 minutes and 5 minutes were 
compared with results taken the previous day without amiloride pre-treatment, see 
Figure 8.
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F ig u re  8.
N a s a l  s e p t u m
IPSI LATERAL
t
Day 2
ImM amiloride
0.9% NaCI or Lactic acid y
Secretions collected 
Time = 2 minutes
Secretions collected 
Time = 5 minutes
CONTRALATERAL
Secretions collected 
Time = 2 minutes
Secretions collected 
Time = 5 minutes
F ig u re  8. N a sa l secretion  w eight co llectio n s fo llo w in g  a m ilorid e  pre-treatm ent o f  
n a sa l cavity, a n d  fo llo w in g  n a sa l cha llenge with isotonic sa lin e  o r  la ctic  acid. 
A m ilo rid e  was hypothesised to b lock  A S I C  receptor channels, lead ing  to 
decreased n a sa l secretion  weights com pared to D a y  1 co llections fo llo w in g  
identica l n a sa l challenge.
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3.7 Physiological nasal secretion collection and nasal challenge with lactic 
acid and amiloride
The second solution used to promote nasal secretory response was 15mM lactic 
acid. From lactic acid’s molecular weight of 90.08g/L to make 1M concentrations, 
0.09008mg/mL was required to make ImM concentrations. Further calculations 
derived that 1.3512mg/mL was required to make 15mM concentrations. Thus, lg 
of lactic acid was diluted with 0.74L of sterile water to achieve the required 
concentration.
Lactic acid was then buffered using sodium hydroxide (NaOH) to achieve the 
desired pH range. Unbuffered lactic acid at low pH would have caused significant 
discomfort when sprayed onto the nasal mucosal lining. Seven point four (7.4) 
mL of lactic acid was buffered with 51|jL of 2M alkaline buffer from a 
commencement pH of 4.5 to a final pH of 7.0. Final pH of the buffered solution 
was confirmed using the Eutech EcoScan pH/°C monitor. This was instilled as an 
aerosol spray in the same manner as the saline spray, into a randomly selected 
nostril of each participant.
Similar measurements of nasal secretion weights were undertaken using the same 
two-filter disc technique as previously with saline spray. Once again, participants 
were invited back the following day for pre-treatment with amiloride spray, and 
the process of nasal secretion collection repeated again, see Figures 6, 7, and 8.
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All nasal mucosal biopsies were carried out within the setting of the ENT clinic 
with resuscitation equipment present. Three (3) nasal mucosal biopsies were taken 
under local anaesthetic from either the right or left anterior aspect of the inferior 
turbinates for each study participant. The inferior turbinate was chosen as the 
biopsy site for ease of access, and also due to previous studies showing that the 
parasympathetic regulation of glandular secretion and vasomotor tone is 
especially prominent in the inferior turbinate (Nakaya M, 2002). Co-phenylcaine 
(lignocaine hydrochloride 5% and phenylephrine) spray was used for its local 
anaesthetic and mucosal vasoconstrictive properties, as previously described by 
Thornton et al (Thornton MA, 2004). Previous descriptions of biopsy techniques 
using cocaine (Fokkens WJ, 1988) were not considered, with regards to the strict 
control and monitoring required for such a controlled substance.
Three sprays were instilled into the chosen nasal cavity, and cotton wool 
impregnated with co-phenylcaine was then placed adjacent to the inferior 
turbinate for 15 minutes thereafter (see Figure 9). Access to the inferior turbinate 
was enabled by a Cottles nasal speculum, under direct visualization using a 
headlight. Three (3) biopsies were taken from the anterior portion of the 
designated inferior turbinate using micro-cutting biopsy forceps once anaesthesia 
had been achieved. Only mucosa directly held up against the cutting forceps blade 
was taken, without further tearing any mucosa adjacent to the biopsy site. 
Haemostasis was secured post-biopsy with co-phenylcaine-impregnated pledgets 
held up against the biopsy site under direct vision.
3.8 Inferior turbinate nasal biopsies
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Two biopsy samples were placed in cryotubes and fresh frozen in liquid nitrogen, 
and stored at -80 degrees Celsius for later PCR quantification of cDNA. The third 
biopsy was immersed and stored in formaldehyde solution at room temperature 
for use in immunohistochemical staining, (Figure 10).
All biopsies were adjudged to be pain free when participants were interviewed 
about their comfort immediately after the biopsy. All participants were 
encouraged to remain within the vicinity of the ENT clinics for a further 30 
minutes to ensure adequate help was available should complications, such as 
persistent bleeding, arise.
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F ig u re  9.
F ig u re  9. In fe r io r  turbinate n a sa l m ucosal b iopsies taken under lo ca l anaesthesia. 
A  chosen nasa l ca vity  w as p re p a re d  with co-phenyl ca ine  sp ra y and  co- 
p h en ylca in e-soa ked  cotton w ool u n til adequate anaesthesia was obtained. Three  
biopsies o f  in ferio r turbinate m ucosa was obtained with cutting biopsy forceps.
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F ig u re  10.
F ig u r e  10. D istrib u tio n  o f  b iopsies f o r  P C R  a n d  im m unohistochem ical staining.
3.9 Purification of total R N A  from human tissue
Purification of total RNA was undertaken with the RNeasy mini kit. Fresh frozen 
nasal mucosal biopsy samples were thawed from -80°Cin ice. Prior to use, beta- 
mercaptoethanol was added to Buffer RLT in a ratio of lOpL per lmL of Buffer 
RLT. Six hundred (600) pL of RLT buffer / beta P-mercaptoethanol mixture was 
added to each tissue specimen for disruption.
Cell wall and plasma membrane disruption to release all RNA contained within 
the sample was carried out with pestle and mortar for 30 seconds, and the lysate 
homegenised by passing the lysate 10 times through an insulin syringe and 20 
gauge needle. This was then centrifuged at 4°C for 3 minutes at 10,000 
revolutions per minute.
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The supernatant was removed into fresh Eppendorf tubes, labeled tubes A, and 
600 microlitres of 70% ethanol was added to each. This mixture was pippetted to 
mix.
Six hundred (600) fiL of solution in tube A was then transferred to 2mL filter spin 
columns tubes and centrifuged for 15 seconds at 10,000 revolutions per minute at 
4°C. The flow through at the bottom of the spin column tube was then discarded.
A further 600|iL from tube A was again added to the filter spin column tubes and 
centrifuged again for 15 seconds at 10,000 revolutions per minute at 4°C. The 
flow through was again discarded.
Seven hundred (700) |iL of Buffer RW1 was then added to the spin column tubes 
and centrifuged for 15 seconds at 10,000 revolutions per minute at 4°C. The flow 
through was again discarded.
Five hundred (500) jiL of Buffer RPE was then added to the filter spin column 
tube and centrifuged for 15 seconds at 10,000 revolutions per minute at 4°C. The 
flow through was discarded.
A further 500(iL of Buffer RPE was added to the filter spin column and 
centrifuged for 2 minutes at 10,000 revolutions per minute at 4°C to wash the spin 
column membrane. The collection tube was then discarded upon removal of the 
spin column.
The filter spin column was placed into new 1.5mL Eppendorf tubes, into which 
30(iL of RNAse-free water was added. This was centrifuged for 1 minute at 
10,000 revolutions per minute at 4°C. Total RNA present at the base of the new 
collection Eppendorf tube was then stored at -20°C for cDNA preparation.
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3.10 Elimination of genomic cDNA
Elimination of genomic cDNA was undertaken with a QuantiTect reverse 
transcription kit. RNA samples stored at -20°C were thawed on ice. Seven (7) fiL 
of RNA were added to a master mix of 2\iL of gDNA wipeout buffer and 5|_iL of 
nuclease-free water per sample in 500|iL Eppendorf tubes. This solution was 
vortexed for a few seconds to mix. The tubes were then placed in a DNA Engine 
PCR thermal cycler and run on gDNA Wipe program for 2 minutes at 42°C. The 
tubes were then removed, centrifuged at 8,000 revolutions per minute at 4°C and 
stored on ice for cDNA reverse transcription.
3.11 Reverse transcription of cDNA
Following wipeout of genomic DNA, single stranded RNA was reverse 
transcribed into complementary DNA (cDNA) using reverse transcriptase enzyme 
from the QuantiTect reverse transcription kit.
Primer-buffer premix was made up with 1 |iL of RT primer mix to A\xh of 5X RT 
buffer. A total of 5|j.L of premix was required for each sample reaction.
A master mix comprising 5|iL of premix to 1 (iL of RT enzyme was then made up. 
This was vortexed to mix thoroughly.
Six (6) fiL of this master mix was added to 14(iL of each single stranded RNA 
sample and vortexed on ice. This solution was then centrifuged at 8,000 
revolutions per minute for 15 seconds.
The samples were then ran on the DNA Engine thermal cycler QuantDNA 
program for 15 minutes at 42°C and 3 minutes at 95°C, following which samples
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were centrifuged at 8,000 revolutions per minute for 15 seconds and stored at -20 
°C for further quantification polymerase chain reaction.
3.12 Polymerase chain reaction and purification of cDNA for standards
High-quality nucleic acid templates for PCR amplification were obtained via 
purification with the Wizard PCR Preps DNA Purification System.
Direct purification from PCR amplification
One hundred (100) (iL of Direct PCR Purification Buffer was aliquoted into a 
tube. Thirty (30) to 300(j.L of PCR reaction was added to this, and vortexed 
briefly to mix. One (1) mL of resin was added and vortexed briefly 3 times over a 
1 minute interval.
PCR product purification
A Wizard™ Minicolumn was prepared for each sample to be purified. The 
plunger was removed from the 3mL Luer-Lok™ syringes, and the syringe barrel 
attached to the Minicolumn. The resin/DNA mix was added to the syringe. The 
plunger was inserted, and the resin/DNA slurry pushed into the Minicolumn.
Washing
The syringe was detached from the Minicolumn, and plunger removed from the 
syringe barrel. Two (2) mL of 80% isopropanol was added, and this isopropanol 
was pushed through the Minicolumn with the syringe plunger. The syringe was
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then removed, and the Minicolumn transferred to a 1.5mL microcentrifuge tube. 
This was centrifuged at 10,000 revolutions per minute for 2 minutes.
Elution
The Minicolumn was then transferred to a clean 1.5mL microcentrifuge tube. 
Fifty (50) jliL of Nuclease-free water was added to the Minicolumn and left in 
place for I minute. This was then centrifuged at 10,000 revolutions per minute for 
20 seconds at room temperature. The Minicolumn was now removed and 
discarded, and the DNA stored at -20°C or below for later use.
3.13 ASIC receptor gene quantification with polymerase chain reaction
Primer design
Primers were designed against published gene sequences downloaded from 
Pubrned ('http://www.ncbi.nlm.nih.gov/pubmed/). Table 3 sets out the primers 
used in this study.
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T a b le  3 : P r im e rs  u se d  in  th is  stu d y
Gene Primer sequence
(3-actin 5'-GGACTTCGAGCAAGAGATGG3'(forward) 
5'-AGGAAGGAAGGCTGGAAGAG-3'(reverse)
ASIC-1 5'-GCTATGGCAAAGAGCTGTCC-3’(forward) 
5'-GTCCAGCACCAGGATGTTCT-3'(reverse)
ASIC-2 5 ’ - AC AGGAGCAGAGGCTC ACAT-3 ’ (forward) 
5 ’-CGGGTCTCACAGTCAATCCT-3 ’ (reverse)
ASIC-3 5'-TGGAGGGACAATGAGGAGAC-3'(forward) 
5’-CTGGCAAGAAACAAAGGTC-3' (reverse)
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The QuantiTect SYBR Green PCR (Qiagen) kit was used for amplification of 
cDNA via the Light Cycler ™ 1.0 (Roche), using SYBR Green 1, a ready to use 
reaction mix for PCR. These were used according to the manufacturer’s 
instructions.
The primers were diluted first in a ration of 4microL of primer to 16p,L of PCR- 
grade water.
A master mix was then prepared with the following components in fixed ratios:
lOpL SYBR Green 
0.5f^ L ASIC forward primer
0.5(iL ASIC reverse primer 
7(iL PCR grade water
This made up a master mix of 18|j.L, which was then pipetted into a pre-cooled 
capillary tube in a cooling block. To the capillary tube was then added 2\xL of 
cDNA, which was then sealed with a stopper. This tube was then centrifuged at 
1000 revolutions per minute for 5 seconds in a bench-top centrifuge. The capillary 
tube was then placed in the rotor of the LightCycler machine, and cycled as 
described and compared to similar capillary tubes made up with 2|iL of standards. 
This was repeated for each of ASIC-1, ASIC-2 and ASIC-3 primers.
M aster M ix  So lu tio n
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Study samples were continually monitored during PCR. The samples were 
initially denatured at 95°C for 15 minutes, followed by 35-40 cycles of 
denaturation, annealing, and extension at 95°C for 15 seconds, 55°C for 25 
seconds, and 72°C for 11 seconds. For beta-actin, this was set out as 95°C for 15 
seconds, 55°C for 20 seconds, and 72°C for 20 seconds.
Characteristic melting curves were obtained at the end of the amplification 
process, by cooling the samples to 65°C for 15 seconds, followed by further 
cooling to 40°C for 30 seconds.
Serial ten-fold dilutions were prepared from individual PCR products, to be used 
as standards to plot against the unknown quantity study samples. Quantification of 
data was analysed using the LightCycler ™ analysis software, and values were 
normalized to the level of beta-actin expression for each sample on the same 
template cDNA.
Melting curve analysis
A melting curve is produced following PCR. Due to the melting behavior of DNA, 
fluorescence will decrease with an increase in temperature. With the SYBR Green 
1 format, this is due to separation of double strands and consequent release of 
SYBR Green 1 molecules, resulting in a drop in fluorescence. The whole purpose 
of analyzing the melting curve is to determine the characteristic melting 
temperature of a target cDNA. This temperature supplies information useful for 
product identification and indentification of unwanted by-products, such as
R e a l tim e P C R  c y c lin g  param eters
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primer-dimers. Display and analysis of this data was performed using the melting 
curve analysis tool of the LightCycler ™ software 
(www.qiaaen.com/HB/ primerAssay).
3.14 ASIC receptor localisation w ith im m unohistochem ical staining
Immunohistochemistry was performed on 5 pm formalin-fixed, paraffin- 
embedded (FFPE) tissue sections using a polyclonal antibody to ASIC-3 (1:50) 
and a monoclonal antibody to PGP9.5 (1:50). We specifically targeted ASIC-3 as 
this was the only ASIC receptor to show any significant difference in expression 
between Control and Allergic Rhinitis groups (as documented in the results 
section).
Sections were deparaffmized, and antigen retrieval was performed in 0.01 Km 
Tris-EDTA (pH 9.0) in a pressure cooker, at full steam pressure for 2 minutes. 
Primary antibodies were then incubated on sections overnight at 4°C and detected 
using peroxidase-labeled Envision anti-rabbit or anti-mouse secondary antibodies 
with DAB as peroxidase substrate. As a control, the samples were processed in 
the same manner but using isotype rabbit or mouse IgG, in place of the primary 
antibodies.
For dual-immunofluoresence, sections were subject to antigen retrieval, and then 
incubated overnight at 4°C in a mix of anti-ASIC-3 and anti-PGP9.5.
After washes in TBS, bound antibodies were detected by incubation in a mixture 
of goat anti-rabbit Alexa-488 and goat anti-mouse Alexa-568 (both 1:500) for 2 
hours at 37°C.
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After final rinses in TBS, sections were mounted in 4,6-diamidino-2- 
phenylindole Vectashield. Mounted sections were analyzed, and images were 
acquired using a Leica DF350 FX digital camera and processed using Leica 
FW4000 software.
Immunostained sections were evaluated in a blinded manner without knowledge 
of the clinical status of the patients. Ten non over-lapping high power fields from 
the surface epithelium and submucosal regions were evaluated for expression of 
ASICs 3. The intensity of staining was evaluated as 0, 1+ 2+ and 3+ for no 
expression, weak staining, medium staining and abundant staining respectively
3.15 ASIC receptor pro te in  identification w ith W estern Blotting
1. Gel Electrophoresis Stage
Separating gel was made up and added to 1 cm of top of gel set-up. This was 
layered with ethanol and allowed to set for 5 -10 min. Stacking gel was made up 
in the mean time. When the separating gel was set, the ethanol was removed and 
poured onto the stacking gel. The comb was inserted making sure no bubbles had 
formed. This was left to set for 30 minutes. The amount of protein in samples was 
measured. The hot plate was preheated to 94°C. All samples were made up to the 
same amount (~10ul) using sterile distilled water (SDW). The same amount of 
SDS sample treatment buffer was added in the fume hood and proteins were 
denatured for 5 minutes.
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2. Running blot
The side supports and elastic were removed from the gel and added to the 
chamber. Backing support was added to the other side. Three hundred and fifty 
(350) ml IX running buffer was made up (70 ml 5X buffer and 280 ml dH20) and 
gradually added to the electrophoresis chamber, ensuring no bubbles existed. The 
comb was then carefully removed. Ten (10)ul of molecular weight marker and - 
20ul of sample was added to the wells. This was run at 30mAmps/gel > 500 V > 
20W for approximately 1 hour or until the dye had run to the bottom of gel.
3. Transferring Blot
Four blotting papers and one nitrocellulose were cut. One thousand two hundred 
(1200)ml of transfer buffer was added to the chamber. The blot sandwich was 
made up with:
• White grid
• Two foams
• Pre-wetted blotting paper
• Pre-wetted nitrocellulose
• Gel cut to size
• Pre-wetted blotting paper
• Two foams
• Black grid
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Everything was clipped together and placed in the transfer chamber with the white 
side facing forward to the +ve side. This was run at 80 mA, 500 V, 30 W 
overnight.
4. Blocking Stage
The blot was removed from the sandwich, and Ponceau S solution added. This 
was left for a few minutes to show up proteins. This was then removed by 
washing under the tap. The blot was immersed in blocking buffer and left for 1 
hour. The buffer was then tipped out and the sheet placed on tissue paper.
5. Washing and primary antibody stage
Primary antibody was made up in blocking buffer and 5 ~ 10 ml added to 50 ml 
tubes. The blot was carefully placed in the tube, sealed with parafilm and rotated 
for 2 hours. The blot was removed and washed with 50 ml washing buffer 6 times 
for 5 minutes on a shaker. Secondary antibody was made up in blocking buffer. 
The blot was immersed in antibody and shaken for 1 hour. The washing procedure 
was repeated to remove secondary antibody.
6 . Assay & Substrate stage
Assay buffer was made up and the blot was washed with 10ml twice for 2 minutes 
to prepare for substrate. The substrate was made up just prior to use, and pipetted 
onto blot placed on a plastic sheet. This was left for 5 minutes. Excess substrate
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was removed from the blot and sandwiched between the plastic folder. This was 
then exposed to x-ray film for 30 seconds to 1 minute.
3.16 IM R32 Cell cultures
Proliferation and differentiation media were made up (see Reagents).
Thawing:
Cells were thawed quickly by placing cryovial in a 37°C incubator. The contents 
of the cryovial were then transferred into 5ml medium containing 10% FCS 
(twice as much FCS is needed to initially boost cells; when first passage needed, 
ordinary 5% FCS Proliferation Medium was used) in a sterile 15mL conical tube. 
Cells were spun at RT, 1300 rpm for 10 minutes. The supernatant was discarded 
and cells resuspended in lmL 10% FCS medium. The cells were transferred to a 
culture flask (T75) containing 15mL 10%FCS medium (prewarmed to 37°C). 
These were then labelled and incubated at 37°C, with 5% C02.
Passaging:
Old media from the culture flask were poured off down to approximately 0.5mL. 
The flask was tapped until cells sheeted off from the bottom of the flask. Five 
(5)mL fresh Proliferation Medium (prewarmed to 37°C) was added, and 
remaining cells were rinsed off the bottom of the flask. The medium with 
suspended cells was transferred into a sterile 50mL conical tube. Approximately 
10(iL of cells were removed into a sterile Eppendorf tube for counting. Cells were
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spun at 1300 revolutions per minute, RT, for 10 minutes. Based on cell count, 
cells were resuspended in an appropriate volume of proliferation media and cells 
were passed through a syringe with a 21G needle (green) 3-4 times to break up 
clumps of cells. These cells were transferred to flasks and plates as appropriate. 
(For example, 3x 106 cells in T75 flask will be confluent in 2-3 days).
Differentiation:
Cells were plated to an appropriate number on cell culture plates. At 24-48 hours 
after plating, Proliferation Medium was replaced with Differentiation Medium. 
Cells were allowed to grow for 7- 8 days, with the medium changed every 1-2 
days.
Freezing.
Cells were removed from the bottom of the flask and spun down as in Passaging. 
Based on cell count, cells were resuspended in Freezing Mix (90% FCS; 
10%DMSO) at approximately 5x 106 per mL and lmL placed in each cryotube. 
These were labelled and placed at -80°C overnight before transfer to liquid 
nitrogen.
3.17 Cell C ulture: In  vitro experim ents w ith eosinophil peroxidase in co­
culture w ith  16HBE14o cells.
Eosinophils and their released granule proteins are found in association with 
airway epithelial cells, mucous glands and nerve cells in patients with persistent 
AR compared to control subjects (Godthelp T 1996 and Thornton MA et al,
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unpublished). Since these are the sites at which ASIC-3 expression is also 
distributed, we investigated the effect of eosinophils and, in particular, their 
granule proteins on the expression of ASIC-3 in vitro.
16HBE14o- cells were cultured in minimal essential medium (MEM) 
supplemented with 10% FCS, 1% L-glutamine, and 1% penicillin/streptomycin. 
Eosinophil peroxidase (EPO) was added at 1 (j,g/mL for time points between 1 and 
24 hours. In experiments designed to investigate the role of MAP-kinases, cells 
were pre-treated for two hours with the ERK1/2 inhibitor PD98059 (50|iM). After 
removal of media, total RNA was isolated from the cells with TRI reagent™, 
according to the manufacturer's instructions. cDNA preparation from ljxg RNA 
and real-time PCR for ASIC-3 and (3-actin from cDNA preparations was then 
carried ou t.
3.18 Visualization of ASIC-3 expression by epithelial cells.
The NuLi-1 (normal lung) and CuFi-1 line, derived from a cystic fibrosis patient 
with A508/A508 genotype were used for confocal and fluid secretion studies. The 
cell lines are able to form differentiated polarised monolayers that exhibit 
transepithelial resistance and maintain ion channel physiology for the genotypes. 
After 4-6 weeks of cell culture, the cells formed a polarised confluent monolayer 
with a high transepithelial resistance (TEER) of > 800 O/cm2. Confluent 
monolayers of cells were exposed to EPO l^g/mL applied to the basolateral 
surface for varying time points. The inserts were fixed with methanol and stained 
by incubating with the primary antibodies (rabbit polyclonal anti-ASIC-3 antibody
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from Neuromics diluted to 1:50 in phosphate-buffered saline with 3% bovine 
serum albumin for 1 hour on ice. The samples were rinsed in phosphate-buffered 
saline following blocking buffer incubation, and exposed to the secondary 
antibodies (1:1000) for 2 hours at room temperature. The monolayers were 
counterstained with rhodamine phalloidin (1:200) to highlight the actin 
cytoskeleton in cells for 2 hours at room temperature. Control experiments were 
performed with rabbit IgG controls. The samples were mounted and imaged using 
a Zeiss LSM 710 laser scanning confocal microscope. Images were analyzed 
using ZEN software.
3.19 Statistical analysis and da ta  in terp reta tion
Comparisons of the nasal secretion weights collected was made using paired 
samples of values of nasal secretion weights obtained at baseline, 2 minutes and 5 
minutes. Sample weights in milligrams were added to a datasheet on the 
statistical package Prism data base, from which means, standard deviations and 
standard error of the mean (SEM) as well as other basic descriptive data were 
derived. In this thesis the graphical representation is shown as mean with SEM. 
In addition the programmed allowed comparison of weights by experiment, in 
which case ANOVA, with Bonferroni correction for comparisons of the various 
time points was made, and when specific time points were compared e.g. with or 
without the inhibitor at 2 or 5 minutes, a paired student t-test. For the real time 
quantitative PCR, comparisons were made using ANOVA with corrections for 
multiple comparisons.
Graphs were drawn for comparison of nasal secretion weights following nasal 
challenge with each of the challenge substances, and nasal secretion weights 
following amiloride pre-treatment, to assess for any attenuation of nasal secretion 
following ASICs inhibitor. Direct comparisons were made between ‘Time 0’ and 
‘Time 5 minutes’ time points.
Graphs were also prepared in both scatter format and column format, to show the 
difference in PCR quantification of ASICs in both controls and participants with 
persistent allergic rhinitis.
Comparison of the extent of immunohistochemical staining of ASIC-3 receptors 
between controls and allergic rhinitis patients was also graphically represented. 
Induction of ASIC-3 mediated by eosinophil peroxidase acting via an ERK1/2 
dependent pathway was also demonstrated graphically.
3.20 M easurem ent of airw ay surface liquid height in response to eosinophil 
peroxidase
To determine if ASIC were functional, in vitro measurements of the airway 
surface liquid (ASL) were carried out. These experiments were performed as 
described previously (Coakley RD 2001 ) and carried out by my colleague, Dr M 
al-Alawi, at the Respiratory Research lab in Beaumont Hospital. Briefly, over a 
period of 40 hours the ASL was intermittently measured to determine the mean 
plateau value of the stabilized ASL height. These results were included in this 
thesis as additional evidence that ASIC receptors are functional.
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C H A PTER  4 -  RESULTS
Functional experiments, with isotonic saline and lactic acid, buffered to pH 7.0 
were carried out to determine if ASIC-3 receptors were activated by acidic 
solutions, and if there were differences between patients with allergic rhinitis 
compared to healthy controls. In physiological experiments carried out with 
isotonic saline, no significant differences were noted between controls and 
participants with AR. These results are thus not documented.
Lactic acid was buffered using sodium hydroxide (NaOH) to achieve the desired 
pH range (see Methods chapter). Final pH of the buffered solution was confirmed 
using the Eutech EcoScan pH/°C monitor.
There were 23 subjects in the control group and 19 subjects with a clinical 
diagnosis of persistent allergic rhinitis, as defined by the ARIA criteria (Bousquet 
J 2008). Nasal challenges with lactic acid were performed before and after 
pretreatment with ASIC-inhibitor amiloride, (lxlO"3M), and at the specified time 
points, nasal secretion weights from the ipsilateral and contralateral sides of the 
challenge were recorded. Lactic acid administration caused no significant 
uncomfortable sensation, e.g. burning or irritation in either subgroup of subjects. 
There was a significantly increased nasal secretory response on the ipsilateral side 
in patients with AR in response to lactic acid. After 5 minutes, the secretions had 
increased from a baseline of 3.42±0.80mg to 10.17±2.61mg, p=0.01 and these 
enhanced secretary responses were then blocked by amiloride (lmM). Lactic acid 
induced secretions were noted to be attenuated by pretreatment with amiloride, 
see (Figure 11 A). Although there was still a significant rise in secretions after 5
4.1 Secretory responses to topical application of lactic acid
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minutes even after amiloride-blockade, the increase in secretions were not as high 
as when measured without amiloride-blockade.
There was also a smaller but significant increase in the secretions in the control 
subjects after lactic acid administration, rising from a baseline of 3.76±0.65mg to 
8.86±2.23mg, p=0.02. However, amiloride did not prevent this rise; in the 
presence of amiloride pre-treatment, secretions still rose from 3.58±0.55mg to 
7.79±1.10mg, (p=0.008), which may suggest that the response might not be 
mediated through ASIC channels (Figure 1 IB).
Secretory responses were also recorded on the contralateral side to which the 
lactic acid had been administered, to assess if there was a reflex response to the 
administered lactic acid. This data showed there were no significant changes in 
contralateral secretions in either the AR (Figure 11C) or control groups (Figure 
1 ID), in response to lactic acid.
Appendices 2 and 3 record nasal secretion weights.
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Figure 11 A-D Lactic acid induces a significant increase in secretion in the 
ipsilateral nasal mucosa which is attenuated by pre-treatment of the ipsilateral 
nasal mucosa with amiloride (lx l0-3M) in subjects with allergic rhinitis but not 
control subjects (A and C). Graph shows the changes in nasal secretion for
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subjects with allergic rhinitis who were administered lactic acid (pH=7.0)(open 
boxes) or pre-treated with amiloride and then challenged with lactic acid (closed 
boxes) as described in the Methods section. Lactic acid did not induce significant 
increased nasal secretions in the contralateral side in either AR or control 
subjects (B and D).
I l l
Various ASIC receptors in nasal biopsies were quantified and compared, to assess 
which types were upregulated, and whether these were upregulated solely in AR 
patients.
Real time PCR quantification of ASIC receptors in nasal biopsies demonstrated 
the presence o f ASIC-1 in both control and AR subjects but there was no 
significant difference in the level of its expression between the AR and control 
subjects (Figure 12A). There was clear evidence of upregulation o f ASIC-3 
receptors in patients with AR compared to healthy control subjects (Figure 12B 
and Figure 13) (p<0.02). There was no appreciable detection of ASIC 2 in control 
or AR subjects (data not shown).
Appendices 4,5 and 6 record ASIC1, ASIC2 and ASIC3 quantification.
4.2 Real time PCR of inferior nasal turbinate biopsies
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Figure 12 A -B .
A
AR Control
B
AR Control
Figure 12 A-B. Airway expression o f  the mRNA fo r  ASICS 1(A) and 3(B) 
quantified by real time PCR is shown. Nasal biopsies from  the inferior turbinate 
o f  control (n—12) and allergic rhinitis subjects (n=13) were obtained as 
described in the Methods section. The DNA was extracted, reverse transcribed, 
subjected to real time PCR and the levels o f  expression normalized to the 
housekeeper b-actin. Expression o f  mRNA from  ASIC-1 was detected in a few  
subjects, no ASIC-2 was detected in any subjects (data not shown) and there was 
expression o f  A S IC S  in both control and A R subjects. The level was increased in 
the AR subjects, p  —0.02.
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F ig u re  13
ASIC3 expression is higher in patients with allergic rhinitis than in controls
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Figure 13. There is higher expression of ASIC-3 mRNA as quantified by real time 
PCR in patients with allergic rhinitis compared to controls.
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Since ASIC-1 transcriptional levels did not differ between AR and control 
subjects and because there was no appreciable detection o f mRNA for ASIC -2 in 
the nasal biopsies, we proceeded only to localize the presence of ASIC-3, which 
was expressed in high levels in the AR subjects. This was alluded to in the 
Methods section.
There was immunostaining for ASIC-3 on the epithelial surface and epithelial 
glands in both AR (Figure 14A) and control subjects (Figure 14B). An isotype 
control antibody showed no staining (Figure 14C). There was also strong staining 
in the nasal mucous glands (not shown). Semi quantitative counts of the degree 
o f epithelial cell staining intensity were performed by two independent observers. 
The results show an increase in the staining of ASIC-3 in the subjects with AR 
compared to the control subjects, p=0.05 (Figure 14D).
4.3 Immunohistochemical localisation of ASICS-3 in the nasal epithelium
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Figure 14 A-D.
Figure 14A-D. Immunohistochemical localization o f  ASIC-3 on biopsies o f  the 
inferior turbinate fo r  control and AR subjects is shown. The specificity o f  staining 
is shown in 14C where there is no staining when an isotype antibody was used. 
The predominant staining o f  ASIC-3 was by epithelial cells and mucous glands 
although there was also some patchy staining on mononuclear cells in the 
submucosa. The staining was more prominent on the surface epithelium o f  the 
subjects with AR (14A) compared to the control subjects (14B), as shown 
graphically (14D).
Staining of nerve cells was performed with an antibody to the nerve cell marker 
PGP 9.5 and the sections were then co-stained with the antibody to ASIC-3 
(Figure 15).
Several areas of co-localization are clearly present in major nerve bundles and in 
small fibers in the airway epithelium, but overall the neural staining was not as 
strong as that seen in the epithelium. There was no appreciable difference in the 
neural staining o f PGP 9.5 immunoreactiye nerves between controls and AR 
subjects (Figure 15 A-C). Laser capture microdissection o f PGP-stained sections 
was performed to enrich the neural tissue, to specifically quantify neural mRNA 
for ASIC, but there was insufficient neural tissue obtained from the nasal biopsies 
to extract sufficient mRNA to provide a meaningful result (data not shown).
4.4 Immunhistochemical localisation of ASIC-3 to nerves
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F ig u re  15 A - C
Figure 15 A -C  Immunohistochemical localisation o f  neural ASIC-3 on biopsies o f  
the inferior turbinate fo r  control and AR subjects are shown (A-C). Staining o f  
ASIC-3 (green staining A and C) was seen in small nerve fibres (red staining in 
B) within the epithelial cells and in larger nerve bundles. Figure 14C shows the 
merged images showing co-localisation o f  the ASIC-3 within nerve fibres.
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Previous studies have shown that eosinophils and their released granule proteins 
are found in association with airway epithelial cells, mucous glands and nerve 
cells in patients with persistent AR compared to control subjects (Godthelp T 
1996 and Thornton MA et al., unpublished). These are the sites at which ASIC-3 
expression is also distributed. We investigated the effect of eosinophil granule 
proteins on the expression o f ASIC-3 in vitro. IMR32 neuroblastoma cells were 
grown in culture and differentiated to a cholinergic phenotype.
In these in vitro studies, EPO (1 (ig/mL) induced a significant upregulation of 
ASIC-3 at both membrane protein level and at an mRNA (transcriptional) level 
(Figure 16), with the increase in protein and mRNA being evident within the first 
hour and being sustained for 24 hours.
Previously, we have shown in the supervising laboratory that EPO induces 
signalling in these cells via activation of the MEK pathway. Inhibition of this 
pathway with the MEK-kinase inhibitor PD95805 caused a complete abolition of 
this induced ASIC-3 expression. This indicated dependence of ASIC-3 expression 
on ERK activation.
Similarly, in CuFi-1 epithelial cells (Figure 17) there was evidence of apical 
induction of membrane bound ASIC-3 by eosinophil peroxidase at 18 and 24 
hours, (n=4)
4.5 Induction of ASIC-3 expression by eosinophil peroxidase
119
F ig u re  16.
16HBE14o cells: whole cell lysate IMR32 cells: membrane protein
+EPO (1 ng/ml)
ASIC-3
ERK2
+EPO (1 |.ig/ml)
Untreated lh  4h 18h 24h
Sto’ ASIC-3
O .be ■*-* 2 ? ££u 0 4
T3 <CÓ 2
CL
Ili
I  without PD98059 
ra with PD90O59
+EPO (1 pig/ml)
Untreated lOmin lh  4h 18h
pERK
ERK2
Time (h)
Figure 16. Induction o f  A S IC S  is mediated by eosinophil peroxidase acting via 
an ERK1/2 dependent pathway. IMR32 cells were pretreated with EPO fo r  times 
from  1 hour to 24 hours and the level o f  expression by mRNA and Western blot 
were assessed. There was a significant increase in the expression o f  A S IC S  as 
early as 1 hour at both mRNA and protein level. This induced expression was 
inhibited by pretreating the cells with the M EK inhibitor PD98059.
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Figure 17. CuFi-1 epithelial cells showing evidence of apical induction of 
membrane bound ASIC-3 by eosinophil peroxidase at 18 and 24 hours, (n=4).
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4.6 Increased airw ay surface liquid height in response to eosinophil 
peroxidase
To determine if  ASIC were functional, in vitro measurements of the airway 
surface liquid (ASL) were carried out. These experiments were performed as 
described previously (Coakley RD 2001 ) and carried out in conjunction with my 
colleague, Dr M al-Alawi, at the Respiratory Research lab in Beaumont Hospital. 
Briefly, over a period o f 40 hours the ASL was intermittently measured to 
determine the mean plateau value of the stabilized ASL height. In these 
experiments the plateau levels were reached at 12 hours with an average height of 
7.97±0.21|im (n=27), (Figure 18). Basolateral treatment with EPO (l|ig/m L) 
increased the baseline ASL to 19.51±0.66(im (n=6) at 18 hours and to 
14.56±0.42|un (n=5) at 24 hours, p=0.0001. The observed increase was abolished 
using apical amiloride (luM , n=4) dissolved in the FC-72 layer. In further 
experiments, basolateral bumetanide (lOpM, n=4) also completely reduced the 
EPO-induced increase in ASL height. We were unable to dissolve the CFTR 
inhibitor CFTR-172 in the perfluorocarbon and the ASIC-3 inhibitor APETx2 was 
ineffective at inhibiting the EPO induced increase in ASL (n=3), presumably due 
to the residual presence o f ASIC-1.
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Figure 18. Increased airway surface liquid in response to eosinophil peroxidase.
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CH A PTER  5 -  DISCUSSION AND CONCLUSION
DISCUSSION
ASIC expression.
ASIC receptors have been noted to occur in various parts of the human body. 
Their presence in nasal epithelia has yet to be elucidated. In this study we have 
shown that among the six subunits of the ASIC family, both ASIC-1 and ASIC-3 
were detected and expressed in nasal epithelial cells. This was true for both 
control subjects and subjects with AR. However, there was no significant 
difference in the level of expression o f ASIC-1 between the AR and control 
subjects, whereas there was clear evidence of upregulation of ASIC-3 receptors in 
patients with AR compared to healthy control subjects, as evidenced by PCR 
upregulation o f ASIC-3 mRNA. With control subjects having had a similar level 
of expression of ASIC-1 in PCR quantification to AR subjects but substantially 
and significantly less ASIC-3, we therefore suggest that the functional ASIC in 
AR subjects corresponds to ASIC-3, and it is this particular receptor subunit that 
has a role to play in the pathology of allergic rhinitis.
ASIC as a functional entity in the nasal epithelium
In vivo, studies showed that application of buffered lactic acid, pH 7.0, induced a 
significant rise in nasal secretions in AR subjects when compared to individual 
baseline secretions on the ipsilateral nasal cavity in which nasal challenge was 
introduced. This secretion was inhibited by pretreatment with the ASIC inhibitor 
amiloride. Although a similar phenomenon occurred in control subjects, this was
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apparent only to a lesser extent. This would suggest that the ASIC receptors were 
functional in both AR subjects, and to a lesser extent, healthy controls, and 
potentially play a role in nasal secretion.
Although a reduction in nasal secretions was observed following amiloride pre­
treatment, it must be noted that amiloride is not specific only to ASIC-3. It 
inhibits ASIC in general and ENaC. Both ASIC-1 and ASIC-3 were shown to be 
expressed in both AR subjects and controls on PCR experiments in the nose. 
However, in the experimental acidic environment of pH 7.0, ASIC-1 channels 
would not be functional as they only open at a pH of 6.5 (Ugawa S, 2002). 
Therefore, we suggest that at the experimental pH, amiloride must have been 
inhibiting only functional ASIC-3 receptors.
ASIC is localized to nasal epithelial cells and small nerve fibres 
We undertook these experiments to investigate which ASIC were expressed in the 
nose o f patients with AR. Having demonstrated on PCR analysis that only ASIC- 
3 mRNA was increased in A R subjects compared to control subjects, we 
investigated the sites o f expression o f ASIC-3.
Immunohistochemical studies indicated that ASIC-3 expression was localized to 
nasal airway epithelial cells, glands and nerves, and along with functional studies, 
there was a clear difference noted in the level of expression of ASIC-3 by 
epithelial cells between control and AR subjects. ASIC-3 was expressed on the 
apical surface o f epithelial cells in both biopsy samples o f AR subjects and cell 
culture studies after exposure to EPO.
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Since many reports have also described neural expression of ASIC, we co­
localized the channel to nerves by dual-immunostaining nerves with the general 
neural marker, PGP 9.5, and then probed for ASIC-3. In these studies, we 
demonstrated evidence o f staining by small nerve fibers within the epithelium, 
where they may be ideally positioned to detect luminal acidification. There was 
no definite increase in expression o f the ASIC-3 on nerves in the AR subjects, as 
judged by immunohistochemistry, when compared to control subjects. Even 
using laser capture microdissection o f PGP 9.5 - stained sections, there was 
insufficient neural tissue obtained from the nasal biopsies to extract sufficient 
mRNA to perform quantitative analysis.
We also attempted to correlate the level of mRNA expression of ASIC-3 to a 
nerve marker, neurgelin, but found no difference in the expression of ASIC-3 
between the two groups. Hence we cannot state definitely if  there are differences 
in the level of expression o f ASIC-3 on nerves, between AR and control subjects.
Eosinophil granule protein induces expression of ASIC-3
As little is known about the regulation of ASIC channels in the setting of allergic 
inflammation, we investigated a possible role for eosinophils in the induction of 
ASIC-3. This mechanism of induction of ASIC-3 expression relevant to AR was 
suggested by the finding that the eosinophil granule protein, EPO, induced the 
expression o f ASIC-3 via ERK 1/2 in cultured epithelial cells.
In prior immunohistochemical studies, it has been demonstrated that there is a 
marked association o f eosinophils and released eosinophil granule proteins in
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association with nerves and epithelial cells in subjects with AR. These are the 
sites in the nasal mucosa at which ASIC-3 was most abundantly expressed. 
Hence, we speculated that induction o f ASIC-3 may be mediated by eosinophils, 
and in particular, their cationic granule proteins.
We have previously used an in vitro model of granule proteins and IMR-32 
cholinergic cells to study eosinophil and nerve interactions. In these studies we 
have shown that the eosinophil granule major basic proteins, and other eosinophil 
granule proteins, signal and cause activation via the MAP-kinase pathways, in 
particular the MEK ERK1/2 pathway (Morgan RK 2005 ). This leads to a variety 
of cellular effects, including the promotion of cell growth and survival. In other 
recent studies, we showed that EPO activates the expression of the Her2 receptor, 
and that this mediates a signalling cascade, which leads to activation of ERK1/2 
(Walsh et al in review). These studies also showed that EPO induced 
phosphorylation o f ERK as well.
We studied this model and several epithelial cell lines alone and in the presence of 
eosinophil peroxidase over varying time points. In all of these cell lines, there 
was no appreciable expression o f the ASIC-3 at baseline, but there was a rapid 
increase in the transcriptional expression of ASIC-3 within 1 hour o f exposure to 
EPO at both mRNA and protein level. Protein expression of ASIC-3 was most 
pronounced at 18-24 hours in all cell lines studied, and furthermore, ASIC-3 was 
localized to the cell membrane.
Increased ASIC-3 expression was inhibited when the MEK/ERK inhibitor 
PD95089 was used, suggesting that EPO was inducing ASIC-3 expression by
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activating this ERIC pathway. Hence, eosinophil localization to, and release of 
EPO in patients with AR, may promote the expression of ASIC-3.
Furthermore, in vitro, EPO acting via ASIC increased the airway surface liquid 
height, a measure of airway hydration, via a chloride mediated secretion. This 
data suggests that rhinorrhoea in eosinophil-associated allergic rhinitis may be 
due to an EPO-induced expression of ASIC-3.
EPO-induced increase in airway surface liquid height is mediated via ASIC 
There have been prior reports of ASIC-3 expression by epithelial cells, and 
studies suggest that the CFTR and ASIC-3 are co-localised. Furthermore, in vitro 
reports suggest that there is a co-operative interaction of ASIC-3 with the CFTR, 
leading to enhanced chloride ion transport (Coakley RD 2001 ) (Tarran 2004) 
(Boucher 2007). In AR subjects, lactic acid induced an ipsilateral production of 
nasal secretions and pretreatment with amiloride prevented this rise in secretions. 
To further investigate the hypothesis that the enhanced secretion seen in the AR 
subjects was mediated through ASIC-3-associated epithelial fluid secretion, 
additional in vitro studies were performed. Measurement of the airway surface 
liquid height was used as a model to investigate the functional effects of EPO and 
epithelial ASIC-3.
Measurement of the airway surface liquid height is a functional quantitative 
assessment o f epithelial cell ion transport. The rationale to these studies was that 
amiloride is both an ENaC and ASIC inhibitor. By inhibiting ENaC, amiloride 
inhibits sodium reabsorption, thus increasing the ASL height. By inhibiting ASIC,
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amiloride inhibits chloride secretion, thus reducing ASL height. In these studies, 
EPO applied to the basal surface induced a significant ASL expansion at the time 
points that ASIC-3 protein expression was maximal, i.e. 18-24 hrs after exposure 
to EPO.
We suggest that this EPO-induced increase in ASL height was mediated via ASIC, 
and this was borne out by the finding that administration of amiloride, as an 
ASIC-3 inhibitor, resulted in attenuation of the ASL height. This would not have 
occurred if  the prominent channel being inhibited was sodium absorption.
In the presence o f the chloride channel inhibitor bumetanide, there was a 
reduction in ASL height when this chloride channel inhibitor was used. This data 
is in keeping with the previously described co-interaction o f ASIC and CFTR (Su 
X 2006) (Ye JH 2007 ). In conjunction with immunocytochemical analysis that 
demonstrated increased apical ASIC-3 in response to EPO treatment, this would 
suggest involvement o f  ASIC-3 in the EPO-induced hypersecretory response 
observed in airway epithelia.
There is little if  any secretory role to the neurally expressed ASIC-3 in the nose. 
We also investigated possible functional effects o f ASIC-3-expressing nerves, and 
we used a well characterized model of nasal reflex responses. In these 
experiments, a stimulus was applied on one side of the nose and nasal secretions 
on the ipsilateral and contralateral sides were collected and measured. Changes in 
contralateral secretions are mediated via a neural reflex since the nasal septum 
separates the two sides o f the nose. In our studies, only ipsilateral nasal secretions
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were enhanced following nasal challenge with lactic acid, and there was no 
evidence of induced secretions on the contralateral side in either the control or the 
AR subjects. This would suggest that there is little, if  any, secretory role to the 
neurally expressed ASIC-3 in the nose.
Furthermore, it has been suggested that neurally expressed ASIC-3 channels in 
the skin mediate pain responses. In our studies there was no evidence of pain, 
irritation, lacrimation or burning reported by any subjects after the administration 
of the lactic acid, both on the ipsilateral and contralateral nasal cavities.
Hence, while there is evidence o f neural expression of ASIC-3 in the nose, we 
have not shown a definitive function o f these channels. Our physiological 
functional studies, using a lactic challenge, support the idea that the application of 
acid to the luminal surface leads to enhanced nasal secretions, only apparent on 
the ipsilateral side. It is not clear if  these secretions represent mucous release or 
exudation of fluid through epithelial cells. More in vitro work is necessary to 
elucidate this.
_The_ m echanism of rhinorrhoea is through EPO-mediated nasal epithelia- 
associated ASIC-3 expression in AR
There are several novel findings in this work, which is the first description of a 
functional role for ASIC in the nose. For example, this is the first study to show 
how an eosinophil mediator of inflammation induces epithelial and neural 
expression o f ASIC-3, leading to enhanced nasal secretion, and it describes a 
novel role for EPO in the mediation o f chloride secretion. This excess epithelial
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fluid secretion may be relevant to the pathogenesis of rhinitis, as it may contribute 
to the symptom of rhinorrhoea.
In summary, these studies indicate that epithelial cells in patients with AR express 
ASIC-3 receptors. In vitro studies suggest that the increased expression in AR 
may be mediated through the eosinophil granule protein EPO. The function of 
nasal epithelial ASIC-3 channels appears to be that they promote nasal secretions 
and this may be a mechanism for rhinorrhoea, one of the common and 
troublesome features of particular forms o f rhinitis, such as non-allergic 
eosinophilic rhinitis.
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CONCLUSION
In this study we have shown that within the nasal mucosa there is 
immunohistochemical expression of the ASIC-3 ion channel, localized to the 
apical surface o f epithelial cells, airway glands and nerves in patients with allergic 
rhinitis. The increased epithelial expression in allergic rhinitis is due, at least in 
part, to the eosinophil granule protein EPO.
The functional consequence o f increased ASIC-3 expression in an acidic 
environment is an induction and enhancement o f the nasal secretory response, as 
demonstrated by the application o f buffered lactic acid at a pH of 7.0. These 
responses are inhibited by amiloride pretreatment.
We suggest that the function o f nasal epithelial-associated ASIC-3 channels 
appears to be the promotion o f nasal secretions, and this is a potential addition to 
the mechanism responsible for rhinorrhoea, one o f the common and troublesome 
features o f rhinitis.
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A p p e n d ix  2 P h y s io lo g ic a l secretions -  L a c t ic  a c id  and am iloride, ipsilateral
m easurem ents. W e ig h t in  gram s (c  =  controls, ar =  a lle rg ic  rh in itis)
Lactic acid (ipsilateral)
Patients Baseline 2mins 5mins
c23 0.002 0.002 0.003
c24 0.003 0.005 0.009
c25 0.01 0.019 0.046
c26 0.005 0.009 0.002
c27 0.002 0.004 0.005
c28 0.002 0.004 0.005
c32 0.004 0.006 0.008
c34 0.008 0.012 0.005
c35 0 0.009 0.003
c36 0.001 0.001 0.009
c37 0.002 0.001 0.001
c38 0.002 0.003 0.006
c39 0.001 0 0.005
c40 0.004 0.004 0.01
c41 0.002 0.001 0.022
c44 0.005 0.009 0.012
c45 0.011 0.005 0.004
c46 0.007 0.017 0.021
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ar31 0.005 0.026 0.003
ar32 0.009 0.005 0.009
ar33 0 0.005 0.003
a r35 0.002 0.003 0.007
ar36 0.002 0.019 0.034
ar40 0.007 0.003 0.008
ar41 0.006 0.014 0.018
ar42 0.003 0.011 0.013
ar44 0.002 0.003 0.004
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L a c t ic  a c id  and am ilo rid e  (ip sila tera l)
baseline 2mins 5mins
c23 0.003 0.003 0.003
c24 0.002 0.009 0.018
c25 0.004 0.003 0.01
c26 0.002 0.001 0.007
c27 0.003 0.004 0.004
c28 0 0.013 0.003
c32 0.002 0.003 0.005
c34 0.006 0.015 0.002
c35 0.003 0.002 0.005
c36 0.004 0.001 0.002
c37 0.01 0.004 0.004
c38 0.002 0.001 0.012
c39 0.003 0.004 0.009
c40 0.005 0.011 0.012
c41 0 0.002 0.015
c44 0.006 0.015 0.008
c45 0.003 0.008 0.012
c46 0.007 0.007 0.004
ar31 0.007 0.001 0.002
ar32 0.006 0.008 0.002
ar33 0.001 0.015 0.013
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ai'35 0.004 0.002 0.004
ar36 0.002 0.004 0.004
ar40 0.002 0.008 0.009
ar41 0.002 0.019 0.015
ar42 0.001 0.004 0.007
ar44 0.002 0 0.002
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A p p e n d ix  3 P h y s io lo g ic a l secretions -  L a c t ic  a c id  and am ilo rid e , contralateral
m easurem ents. W e ig h t in  gram s (c  =  controls, ar =  a lle rg ic  rh in itis)
Lactic acid (contralateral)
baseline 2mins 5mins
c23 0.002 0.003 0.004
c24 0.002 0.001 0.003
c25 0.011 0.005 0.031
c26 0.003 0.013 0.008
c27 0.002 0.003 0.003
c28 0.003 0.002 0.003
c32 0.001 0.004 0.006
c34 0.002 0.019 0
c35 0.006 0 0.013
c36 0.001 0.006 0.003
c37 0.001 0.005 0.002
c38 0.001 0.001 0.002
c39 0.003 0.008 0.002
c40 0.004 0.005 0.003
c41 0.002 0.002 0.001
c44 0.004 0.007 0.002
c45 0.011 0.005 0.002
c46 0.012 0.006 0.021
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ar31 0.01 0.016 0.004
ar32 0.008 0.007 0.019
ar33 0 0.004 0
ar35 0.003 0.006 0.001
ar36 0.002 0.009 0
ar40 0.007 0.005 0.009
ar41 0.002 0.004 0.002
ar42 0.003 0.009 0.011
ar44 0.001 0.005 0.007
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L a c t ic  a cid  and am ilo rid e  (contralateral)
baseline 2mins 5mins
c23 0.003 0.003 0.003
c24 0.001 0.008 0.005
c25 0.006 0.001 0.009
c26 0 0.004 0.004
c27 0.003 0.003 0.003
c28 0 0.005 0.003
c32 0.001 0.001 0.002
c34 0.003 0.002 0.006
c35 0.008 0.004 0.003
c36 0.006 0.007 0.004
c37 0.007 0.005 0.008
c38 0.002 0.005 0.012
c3 9 0.007 0.003 0.013
c40 0.004 0.003 0.006
c41 0.001 0.003 0.007
c44 0.003 0.007 0.008
c45 0.002 0.008 0
c46 0.007 0.001 0.003
ar31 0 0.016 0.003
ar32 0.01 0.008 0.009
ar33 0.002 0.001 0
141
ar35 0.006 0.002 0.003
ar36 0.001 0.007 0.007
ar40 0.002 0.003 0.004
ar41 0.001 0.01 0.001
ar42 0.001 0.002 0.002
ar44 0.014 0.009 0.01
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A p p e n d ix  4  A S I C - 3  q u an tificatio n
Sample ASIC3 B actin Ratio
al 1223
a2 1629.5
a3 2285.5 35.88 63.7
a5 62820 50.36 1247.42
a6 65280 5079 12.85
a7 27945 309 90.44
a8 60660 5631.5 10.77
a9 4257.5 6072.5 0.7
alO 14245 3311.5 4.3
al3 16030 9714 1.65
a l6 59580 7507 7.94
cl3 17560 1881.5 9.33
c l4 19080 1562 12.22
cl6 37.05
cl8 56.19
143
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A p p e n d ix  5 A S I C - 3  quan tificatio n  g ra p h ic a lly  expressed.
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A p p e n d ix  6 A S I C - 1  and A S I C - 2  q u an tificatio n
Ptts ASICs 1 ASICs 2 average
B-ACTIN
1
B-ACTIN
2 average
al 879.8 864.1 872
a2 1297 1071 1184
a3 1423 1974 1698.5 36.6 35.16 35.88
a4
a5 61220 64420 62820 50.04 50.68 50.36
a6 65150 65410 65280 5170 4988 5079
a7 29880 26010 27945 312.2 305.8 309
a8 60980 60340 60660 5571 5692 5631.5
a9 4528 3987 4257.5 6176 5969 6072.5
alO 14320 14170 14245 3404 3219 3311.5
al3 9780 9405 9592.5 2748 2748
al6 8383 7081 7732 1946 1946
a l l ( c l ) 15270 14530 14900 1865 1898 1881.5
al2(c2) 16180 16380 1280 254.2 254.2
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